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In this feature, leading researchers in the field of microbial
biotechnology speculate on the technical and conceptual
developments that will drive innovative research and open
new vistas over the next few years.
Bioproducts from undefined mixed cultures:
electron pushing
Largus T. Angenent, Department of Biological and Envi-
ronmental Engineering, Cornell University, Ithaca, New
York, NY, USA
Robbert Kleerebezem, Department of Biotechnology,
Delft University, Delft, The Netherlands
A thermodynamic state analysis can inform the biopro-
cess engineer if a biological redox reaction is energeti-
cally feasible. This understanding is especially pertinent
in complex systems, such as undefined mixed cultures
that convert organic wastes, as a result of the many
possible pathways that could operate in sequence or in
parallel (Angenent et al., 2004; Kleerebezem and van
Loosdrecht, 2007; Agler et al., 2011). In theory, the bio-
processing of organic substrates in an open microbial
community-based process will result in the production of
the end-product with the lowest free energy content per
electron. This state can be considered as the thermody-
namic equilibrium state and guarantees a maximum
amount of free energy to be harvested by the microbial
community catalysing the process (Hanselmann, 1991).
In the presence of a strong electron acceptor, such as
oxygen, the end-product of organic carbon conversion is
carbon dioxide (0 kJ e-mol-1, reference state) via com-
plete mineralization. In the absence of an electron
acceptor or external energy source, the end-product is
methane (-23.0 kJ e-mol-1). Combined with the in situ
product separation of a gaseous end-product, these ther-
modynamic properties provide a firm basis for the
anaerobic digestion process. Full-scale anaerobic digest-
ers are, therefore, widely used to treat a wide range of
solid substrates and wastewaters and the generated
biogas is used for heat and electric power production –
of note are the ~30 million domestic digesters in China.
Still, despite these intrinsic advantages, methane is not
the most valuable end-product because as a gas it has a
lower energy density and is harder to store/transport
than a liquid fuel. For this reason, bioprocess engineers
are now looking for ways to produce more valuable liquid
fuels or chemical building blocks from organic residues.
To produce a product that is more valuable than
methane under anaerobic conditions with undefined
mixed cultures, methanogenesis should be prevented. If
aceticlastic methanogens are inhibited by, for example,
lowering the pH from ~7 to ~5.8, acetate (-26.9 kJ
e-mol-1) accumulates because hydrogenotrophic metha-
nogens still maintain low hydrogen partial pressures,
allowing for anaerobic oxidation of intermediately formed
short-chain carboxylates and ethanol. A further decrease
in pH will inhibit hydrogenotrophic methanogens as well,
and will shift the fermentation end-product spectrum
to a mixture of carboxylates (e.g. propionate: -27.0 kJ
e-mol-1; and butyrate: -27.1 kJ e-mol-1) and ethanol
(-30.5 kJ e-mol-1). At longer cell residence times,
n-butyrate is often found at high relative ratios within
the fermentation product mixture. At shorter residence
times and with ready degradable substrates, lactate
(-31.6 kJ e-mol-1) dominates in some cases.
The environmental conditions in the reactor are such
that these fermentation end-products, such as n-butyrate
and lactate, cannot be further oxidized anaerobically. The
production of short-chain carboxylates at relatively low
concentrations (< 50 g l-1), however, is not very attractive
because it requires major efforts to recover them from the
fermentation broth. The future quest in development of
bioprocesses for fuel or building blocks should, therefore,
aim at products that require a limited effort for product
recovery. To date, in situ product separation has been
accomplished by generating intracellular storage poly-
mers (polyhydroxyalkanoates) after aerobic conversion of
carboxylates, but new anaerobic production pathways are
currently under investigation as well. These novel produc-
tion routes reduce short-chain carboxylates to alcohols or
medium/long chain fatty acids that can be separated from
the fermentation broth by precipitation, distillation, or by
concentration in an organic solvent. We believe that the
reduction of carboxylates (also called biohydrogenation or
chain elongation) by pushing electrons into the undefined
mixed culture offers a prosperous route.
In situ upgrading of fermentation end-products by
pushing with external reducing power (electrons) is envi-
sioned to produce:
(i) a single main end-product rather than a mixture; and
(ii) a compound that can be separated from the fermen-
tation broth.
Recently, a ground-breaking study by Steinbusch
and colleagues (2010) demonstrated the production of
Microbial Biotechnology (2011) 4(2), 109–137 doi:10.1111/j.1751-7915.2010.00245.x
© 2011 The Authors
Journal compilation © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd
n-caproate [i.e. hexanoate (-27.2 kJ e-mol-1)] with an
undefined mixed culture under anaerobic conditions after
complete inhibition of methanogenesis with an antibiotic
compound. The microbial communities catalysed a
biological two-carbon chain-elongation reaction with
n-butyrate to form n-caproate, using electrons from exter-
nally supplied ethanol that was oxidized to acetate. Impor-
tantly, this C6 carboxylate is relatively easy to separate
from water because of its maximum solubility of ~10 g l-1
at 30°C. To generate a valuable fuel, the extracted
n-caproate with an energy density of -144.8 kJ C-1,
should be further upgraded to, for example, n-hexanol
with an energy density similar to ethanol and n-butanol
(-182.7 and -171.4 kJ C-1); or even better alkanes
(-178.6 kJ C-1), by additional external reactions.
Future research should focus on different methods to
accomplish electron pushing: electrons can be supplied
in many forms other than ethanol, such as by adding
synthesis gas (syngas: mainly hydrogen and carbon mon-
oxide); or directly at the cathode in bioelectrochemical
systems. Particularly interesting of the latter system is that
energy levels at which electrons are introduced can be
manipulated by the power supply, or that hydrogen gas
can be generated within the bioprocess at the cathode.
Recently, researchers have demonstrated that organic
molecules can be produced from carbon dioxide in a
biocathodic compartment, whereas the electrons were
generated from organic waste oxidation in the bioanodic
compartment (Clauwaert et al., 2008).
Thermodynamic estimates can help to predict which
chemicals may accumulate when an external electron
donor is supplied. Molecular hydrogen is a stronger elec-
tron donor (-40 kJ e-mol-1) than most (but not all) organic
compounds, and therefore the net driving force in the
system still aims for production of organic carbon in its most
reduced form (methane). Upon selective inhibition of
methanogenesis, as suggested above, there is a driving
force for the production of other strongly reduced organic
molecules. We also want to point out that, most likely, the
production of strongly reduced compounds will be stimu-
lated by carbon limited operational conditions. In addition,
the end-product composition will depend strongly on
the microbial community structure in the system and the
extent to which the microbes are capable of harvesting the
small amounts of energy available for the electron pushing
reactions. Classical tools can be used to drive
the process in a required product direction, such as bio-
augmentation, adaptive evolution or selecting specific
process conditions. Finally, ecology theory should be
applied to synthesize communities that are stable to per-
turbations. After accomplishing these tasks successfully,
we predict that undefined mixed cultures (carboxylate plat-
form) will be integrated within a biorefinery concept with
other platforms, such as sugar platform (ethanol), syngas
platform (hydrogen and carbon monoxide) or renewable
electricity platform (electrons) to generate bioproducts that
can be upgraded further to bulk chemicals or liquid fuels.
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Looking through the crystal ball: where will our next
generation drugs come from?
Ananda M. Chakrabarty, University of Illinois College of
Medicine, Chicago, IN, USA
Starting from recombinant DNA and production of indus-
trial quantities of human insulin by gene cloning in
Escherichia coli to the present day synthetic biology
through chemical synthesis of a complete genome and
introducing it in specific Mycoplasma strains or the role of
gut microflora in obesity and other modern day illnesses,
microbial biotechnology has come a long way. A classical
example of the role of soil microorganisms in alleviating
diseases is the production of antibiotics giving rise to a
huge anti-infective industry. With the decline in the search
for new antibiotics, and with the emergence of new infec-
tious agents, or even aggressive forms of cancer, it is
imperative that we seek help from bacteria, particularly
the difficult to treat pathogenic bacteria causing chronic
infections and having long-term residence in the human
body, for fighting the life-threatening diseases.
Take for example the case of cancers, HIV/AIDS,
malaria or tuberculosis, for which, in spite of years
of research, no good drugs or vaccines exist. This is
because these disease agents are very smart and quickly
change the target(s) for the drugs or the epitope(s) for
vaccines. The current technology used by the pharmaceu-
tical industry is to rationally design inhibitors as drugs
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against various single targets that are important for
disease progression. Similar is the case for targeting key
surface epitopes in pathogens for eliciting neutralizing
antibodies as candidate vaccines. The pathogens quickly
change such targets or epitopes, thereby becoming
drug-resistant or making the vaccine ineffective. The
pharmaceutical industries’ solution is to use cocktails or
combination of drugs, as in the treatment of HIV/AIDS or
cancers, leading to high costs of treatment and potential
problems of multi-drug resistance.
So what’s the solution? What’s needed are not ratio-
nally designed single-target drugs or vaccines directed
towards key components of the pathogen, but intelligently
designed drugs that will target multiple components of the
disease agents, as well as block the host functions that
are required for pathogen entry and propagation. That’s
not easy to design and is beyond our pharmaceutical
industry’s reach. That’s where the evolutionary wisdoms
of bacteria come in.
It is now becoming apparent that bacteria, particularly
certain pathogenic bacteria that cause chronic infections
in human bodies by forming biofilms on epithelial cell
surfaces and establishing some kind of symbiotic relation-
ship and long-term residence, possess the evolutionary
wisdom of 3 billion years. Such bacteria, Pseudomonas
aeruginosa for example, during chronic infections con-
sider the host body as their habitat and try to protect their
turf from other invading disease agents that can cause
harm or kill the host, thereby depriving the bacteria of their
sanctuary. Such invaders could be cancers, viruses such
as HIV/AIDS or parasites such as the malarial parasite
Plasmodium falciparum or the toxoplasmosis-causing
parasite Toxoplasma gondii. To keep such invaders in
check, P. aeruginosa has developed an exquisitely and
intelligently designed weapon, a copper-containing peri-
plasmic protein termed azurin, which is released when P.
aeruginosa is exposed to its enemy such as a cancer. On
release, the weapon azurin enters preferentially to cancer
cells and stops them on their tracks by interfering in mul-
tiple steps including inhibition of cellular signalling, inhibi-
tion of angiogenesis and induction of apoptosis (Fialho
and Chakrabarty, 2010). The same weapon is also
released when P. aeruginosa is exposed to AIDS-causing
HIV-1 virus, and significantly inhibits viral growth by not
only binding the viral envelope protein gp120, but also
host proteins CD4, ICAM-3 and DC-SIGN (Fialho and
Chakrabarty, 2010). If the host receptors or transport
agents are blocked, and if the interference is at multiple
steps, the disease agents such as cancers or the HIV/
AIDS virus will have problems eliciting resistance to such
a bacterial weapon. Unlike Meningococci or Gonococci
that cause infections in brain meninges, P. aeruginosa is
not known to reach the brain. It is thus interesting to note
that the Meningococci or Gonococci have deliberately
modified their azurin-like weapon, called Laz, which has
an additional 39 amino acid moiety in the N-terminal of
azurin, called an H.8 epitope. This epitope allows Laz to
cross the blood–brain barrier to fight brain tumours such
as glioblastomas (Hong et al., 2010), and potentially
allowing other drugs to cross the blood–brain barrier for
the treatment of brain-related pathologies (Hong et al.,
2010). Thus the weapons are intelligently designed and
appropriately modified to attack the invaders depending
on the bacteria’s habitat.
Two questions!!! Because there are many cancers,
many viruses and many parasites, is azurin the only
weapon that P. aeruginosa uses to keep various invaders in
check, or does P. aeruginosa use other weapons as well?
Also, is P. aeruginosa the only bacterium that produces
protein weapons to keep multiple disease agents
in check or are there other bacteria that produce similar
weapons? We have shown that P. aeruginosa produces
other proteins with anticancer activity, such as arginine
deiminase or Pa-CARD (Fialho and Chakrabarty, 2010),
and we, as well as a group in Portugal, have isolated
another secreted protein from another pathogenic bacte-
rium that demonstrates anticancer and anti-HIV/AIDS
activity, clearly suggesting that bacterial protein weapons,
or peptides derived from them, could potentially be our next
generation promiscuous drugs, where a single drug targets
such major diseases as cancers, HIV/AIDS and others.
It is also interesting to point out that a single candidate
drug such as azurin not only has activity against cancers,
HIV-1 virus, P. falciparum and T. gondii, thereby poten-
tially being useful in the treatment of AIDS patients with
sarcomas or co-infected with malarial and other parasites,
but azurin can also prevent the emergence of cancer (Das
Gupta and Chakrabarty, 2009). This is very important in
preventing the relapse of a cancer, after the cancer is
treated, requiring the patient to take azurin lifelong as a
preventive measure. Eleven US patents and many inter-
national patents have been issued to the University of
Illinois to cover the potential utility of Laz, azurin, and an
azurin-derived peptide P28, in the treatment of cancers,
HIV/AIDS and malaria. Similar patent applications have
been filed for the other promiscuous protein and peptide
drugs by an Indian company Amrita Therapeutics (http://
www.amritatherapeutics.com).
Will such bacterial protein or peptide drugs work in
the real world? A company CDG Therapeutics (http://
www.cdgti.com) in Chicago, under guidance from the US
FDA, is evaluating the toxicity and side-effects of a chemi-
cally synthesized 28 amino acid peptide derived from
azurin, called P28, in patients with advanced cancers and
where no drugs are working. P28 not only proved to be
non-toxic and non-immunogenic in animals but showed
no side-effects, even at maximum tested concentrations,
in such patients. Although efficacy is not evaluated in
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phase I human clinical trials, the early results with P28
show interesting beneficial effects in such patients with
advanced cancer where no other drug is working. Thus I
believe that more such potential multi-disease-targeting
drugs will be isolated and evaluated in the near future,
clearly indicating that bacterial pathogenesis is not nec-
essarily all evil, and something good can come out of it.
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The complete catalogue of life: an end or
a mean?
Pascale Gaudet and Amos Bairoch, Swiss Institute of
Bioinformatics, Geneva, Switzerland
In the past 20 years, a multitude of new techniques have
helped us peek into the cell at a scale and precision
orders of magnitude higher than what have been able
to observe until then. With the current rate of technologi-
cal progress it will be possible in the next 20 years to
accurately catalogue the parts list of almost every repre-
sentative organism in the biosphere. In practical terms,
this means we will have access to complete and correct
genomes, transcriptomes, proteomes, metabolomes,
interactomes – insert your favourite ‘ome’ here – for mil-
lions of different organisms. In other words, we will have
‘captured the complete biome’.
While having a list of parts is of course a very useful,
worthwhile and difficult goal, making sense of it is even
more challenging. To do so, we need to have an accurate
model of any cell state whether as a single entity or as
part of a community, a tissue or a complex network of
interconnected life entities. With the current computing
technology this is not feasible, thus we are bound to seek
short cuts and simplifications in our attempts to model life.
We need to represent what is known about biological
processes into retrievable and computable data objects –
aka annotations. This is where biocuration is crucial.
Biocuration, which can be described as the translation
and integration of biological information into an organized
form such as a database, aims to facilitate the analysis of
complex biological data. Biocurators and bioprogrammers
are exploring techniques to help with data extraction
and data representation. This area of research stands at
the boundary between experimental research, informat-
ics, statistics and even philosophy. The International
Society for Biocuration (http://biocurator.org) has been
created in 2009 to promote exchanges between experts
in this rapidly moving area.
The road is long before we will have captured the earth
biome. To do that we have to insure that the foundations
of the corpus of biocuration that will be necessary to
model life processes is robust. This can only be achieved
by a collective effort that aims to overcome three main
roadblocks in our progress towards translating genomic
data into practical applications:
i. Models for data representation are poor and with few
dimensions. Biologists have traditionally used hierar-
chical lists of terms as a way to represent biological
entities. In recent years there has been much improve-
ment in the representation of data by using much more
formal descriptions of biological entities using ontolo-
gies. In an ontology, each entity is defined with relation-
ships to other terms in the ontology. Many different
types of relationships can be captured (is_a, part_of,
develops_from, etc.). The advantage of this type of
description for modelling biology is that it allows com-
puting not only across terms, but also on how terms
relate to each other. There are several ontologies used
by biologists, the most widely used one being the Gene
Ontology (Gene Ontology Consortium, 2010). Ontolo-
gies are a part of the wider ‘semantic web technologies’
(http://semanticweb.org) that allow different types of
data to be represented in a consistent and compatible
manner. The next challenge is in relating all those
lexicons covering different areas of the biological space
to support more complex data analysis, to work towards
multidimensional data representation and querying.
ii. It is still very difficult to extract information pertinent
to the specific question we are trying to answer from
all the ‘noise’ in the data. The information we have
in databases has variable confidence levels. All
the knowledge we have accumulated in biology is
obtained through the interpretation of a measurement
of some parameter: for example, an enzyme activity
may be measured by the absorption of its substrate
or product; the role of a gene in development is
often measured by the phenotype of a mutation; etc.
Without a complete understanding of the biological role
of the protein, the results of some of those experiments
can be misleading. For example, mutations in a tran-
scription factor can have pleiotropic effects,
some of which may be very downstream from the
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biochemical role of the protein. In addition to different
types of experiments having different degrees of
remoteness from the event being interpreted, different
experimental set-ups have different degrees of reliabil-
ity. Right now very few databases have ways to capture
the confidence of different experiments. Low-
confidence annotations (especially from experiments
with low-confidence read-outs; rather than low-
confidence data) can be extremely valuable for ‘gold
panning’ approaches, where some ‘weak’ information,
especially when confirmed by other data (which can be
weak as well), may be valuable to provide testable
hypotheses. However, that involves designing tools
that can triage the high-quality, high-confidence data
when appropriate, and look through low-confidence
data when there is other data supporting them. The
hope is that this will result in bioinformatics tools
becoming more successful at finding gold nuggets!
iii. There is still much that needs to be learned about the
functioning of cells. This goes a long way into explaining
why much of the efforts in biological research
are focused on information collection. Experimental
research is of course where this starts and ends:
the information, encapsulated in databases is used
to build models, which are used to build new hypoth-
eses. We are still struggling with highly noisy high-
throughput technologies. This means that we cannot
use currently obtained experimental results without a
significant overhead of statistical and methodological
filtering. Getting a reliable knowledge signal in the
background noise of the data is a tedious Sisyphean
task. As soon as one manages to solve the problem for
a given set of data, the technology has already moved
forward and one needs to come up with new tools (a
good example is the progressive move from micro-
arrays to deep RNA sequencing for gene expression
studies).
Ultimately, the goal is to more accurately and rapidly
answer meaningful questions having a direct impact on
medical, agricultural and biotechnological issues. The
hope is that all this accumulated data will help reduce the
lag time between identifying a problem – for example: an
emerging crop infectious disease – and its solution – in
this case it could be the identification of a resistance
mechanism against this pathogen. The complete cata-
logue of life, when it will be available, will provide the
means to address those questions.
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Towards intelligent vaccines: the VAC-CHIP
Carlos A. Guzman, Department of Vaccinology and
Applied Microbiology, Helmholtz Centre for Infection
Research, Braunschweig, Germany
Kenneth N. Timmis, Environmental Microbiology Labora-
tory, Helmholtz Centre for Infection Research, Braunsch-
weig, Germany
Vaccines can be exploited to prevent infections and
other diseases (e.g. cancer) and, as a result, benefit
both vulnerable populations (individual physical and
mental discomfort and loss of work are avoided, and
transmission is reduced) and dependent economies (the
cost of treatment and loss of productivity) (Taylor et al.,
2009). They are also increasingly proposed as a thera-
peutic approach for existing diseases (e.g. infections,
cancer, autoimmunity), either as a stand alone measure
or in combination with standard treatments, and thereby
offer alternative clinical solutions (Riley et al., 2008;
Chen et al., 2009; Dougan and Dranoff, 2009; Garren,
2009; Trimble and Frazer, 2009; Wraith, 2009; Andersen
et al., 2010; Röhn and Bachmann, 2010). Moreover, the
use of vaccines for non-health-related issues, such as
birth control, is being explored both in humans and
animals (Naz et al., 2005; Hardy et al., 2006; Bowen,
2008; Fayrer-Hosken, 2008).
Vaccine development, use, efficacy and safety are,
however, complicated by their intervention in a finely
tuned and regulated immune system that, when per-
turbed, does not always respond in the desired manner.
Specifically: immune responses to a given antigen
may, inter alia, be too specific, too unspecific, too weak,
too strong, too short-lasting, induce auto-immune/
disregulated reactions, etc. It follows that it is not sufficient
to stimulate a strong response, but is also important to
fine-tune the elicited response according to the specific
clinical needs. Stimulation of the wrong response pattern
might even lead to severe consequences (Salemi and
D’Amelio, 2010), as it was the case for the first vaccine
candidates against the respiratory syncytial virus, which
promoted more severe clinical forms of disease in vac-
cinees (Fulginiti et al., 1969). Thus, considerable effort
has in recent years been invested in developing different
antigenic structures, more effective immunomodulators
as co-immunogens (Ebensen and Guzmán, 2008), new
antigen delivery systems (Liniger et al., 2007; Roy and
Noad, 2008; Skountzou and Kang, 2009; Chadwick et al.,
2010) and systems for targeting antigens to specific
immune compartments/tissues (Ghosh et al., 2006;
Tacken et al., 2006; Weiner et al., 2010), etc., in order to
modulate both the intensity and quality of the immune
responses to vaccine candidate antigens. Though these
efforts have considerably improved the art of vaccinology,
basic problems and variations in immune responses
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still exist. For example, in the case of multicomponent
vaccines it is difficult to address the issue of immunodomi-
nance and ensure optimal responses to all antigens in the
formulation. Another challenge of some multicomponent
vaccines is the need for different components of the for-
mulation to stimulate different effector mechanisms (e.g.
induction of neutralizing antibodies against one compo-
nent and cytotoxic T lymphocyte responses against
another). Moreover, in addition to the vagaries of general
immune responses to diverse antigenic stimulations,
there is a substantial diversity of immune responses of
different individuals to the same immunogen, qualitatively
and quantitatively, and even a diversity of immune
responses in the same individual, according to age/
health/hormonal status, such that a vaccine working opti-
mally in the majority of vaccinees may work poorly or
adversely in others (Guy, 2010).
Given the diversities of antigens, antigen formulations,
general immune responses and individual specific
responses, what is needed are intelligent vaccine
systems (IVS), which are able to make and deliver anti-
gens in an appropriate manner over time, while continu-
ously monitoring and adapting to the immune responses
occurring. Current advances in medicine, immunology,
vaccinology, biosensors, nanotechnologies and cybernet-
ics should render this dream feasible.
Imagine the following: a retrievable or absorbable
micro-capsule – the VAC-CHIP – is embedded into an
appropriate tissue. The capsule consists of a vaccine
production module, a vaccine export system, a system
for collection of body fluids, a system for analysing a
battery of immune system effectors and products, and/or
proxies/signatures thereof, and a microcomputer control-
ler programmed to (i) analyse in real time immune
responses to individual antigens, (ii) direct the new pro-
duction and delivery of antigen to the immune system
(either stored or de novo synthesized antigens or nucleic
acids encoding for the antigens of choice, which will also
enable optimal post-translational modifications), as and
when required to achieve an optimal predetermined
immune status, (iii) send to the ‘Vaccine Centre’ (VC) all
data, and warn of any unwanted responses (e.g. cytok-
ine storm by therapeutic interventions), and (iv) shut
down antigen production, once the desired immune
status has been achieved (e.g. by shutting down antigen
production and/or starting an immunization sub-program
leading to the stimulation of Treg cells (Corthay,
2009; Josefowicz and Rudensky, 2009; Nizar et al.,
2010; Sun et al., 2010), and notify the VC that the immu-
nization has been completed. Ultimately, communication
between the VAC-CHIP and the VC should be automatic
and direct, in real-time, although initially would probably
involve manual readings taken by the patient, via an
intermediary monitor-transmitter – probably based on a
smart phone – which could monitor signals emitted by
the microcomputer of the IVS, transmit them to the VC,
receive instructions from the VC and transmit these to
the microcomputer.
Once the desired immune response has been
achieved, the VAC-CHIP could either be removed, or left
in place, if absorbable. In the latter case, it is possible to
imagine two scenarios. If residual biological components
represent no significant disadvantage vis-à-vis toxicity/
immune responses/subsequent immunizations, and the
capsule itself is made of material that remains intact
for the immunization period but is reabsorbed soon
thereafter, then no further action would be necessary. If,
however, the VAC-CHIP components present a potential
risk, it is possible to imagine two further elements:
one would be a VC-controllable biodestruct module
that would contain/synthesize enzymes to degrade
any remaining biological components (antigens, DNA,
immunomodulators, etc.), which would themselves
auto-proteolyse upon instruction from the VC, and a
VC-controllable capsule destruct system, involving
release of a chemical that would render the capsule
material degradable and absorbable.
The VAC-CHIP should enable sequential administration
of poorly immunogenic and immunodominant antigens,
thereby guaranteeing optimal responses to both, as well
as sequential delivery of vaccine formulations aiming at
the stimulation of different effector mechanisms (i.e.
dynamic prime-boosting).
It is also possible to imagine IVS systems that measure
antigens as analytes and are programmed to deliver spe-
cific antibodies in response to the specific readouts. In this
case, the IVS could be used for passive immunization (by
supplying preformed antibodies or by manufacturing
recombinant antibodies) of neonates and other popula-
tions that are immunodeficient, immunocompromized or
requiring antibody therapy (e.g. patients infected with
rabies; at risk from developing septic shock; etc.). Other
potential applications might include a multicomponent
antibody-based IVS that would monitor cognate antigens
in an infant infectious disease control system, and one
comprehensively targeting regionally relevant toxins
that would effect therapy of snake/scorpion/spider bites
without the need to identify the toxin before treatment, etc.
Indeed, the basic concept of a therapeutic implanted chip
that imports, measures and interprets a body analyte and
exports an appropriate dose of a therapeutic agent, could
be exploited in many therapeutic scenarios, including
chronic diseases like diabetes and other hormone defi-
ciencies, cancer, etc.
Current developments leading to the identification
of molecular signatures for vaccine efficacy, and the
advent of systems biology-driven approaches to model
responses to infection and/or vaccination (Pulendran,
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2009; Querec et al., 2009), will pave the road to the ratio-
nal selection of proxies/analytes for decision-making by
the VC. Approaches based on IVS might find an initial
application for therapeutic vaccines or prevention of dis-
eases caused by intracellular pathogens, which require
complex responses against multiple antigens in order to
confer efficient protection (e.g. CMV, HIV, tuberculosis,
chronic hepatitis). They might be also the technology of
choice for poor responders to vaccination (e.g. elderly,
newborns). Most importantly, IVS would constitute a novel
building block of personalized medicine, in conjunction
with the current unravelling of the genetic basis of host
responses and susceptibility to infections (Sancho-
Shimizu et al., 2007; Blackwell et al., 2009; Flores and
Okhuysen, 2009; van de Vosse et al., 2009).
It is also worth noting that an implanted IVS, or its
therapeutic counterpart, would facilitate compliance in
prevention and therapy treatment programmes involving
populations, such as infants, the elderly, psychiatric
patients, etc., or in judicial situations, where compliance
may be problematic.
Although IVS might now seem to be just a dream, the
nanomaterials, miniaturization and microfluidics technol-
ogy to develop them is advancing rapidly (Heller, 2006;
Myers and Lee, 2008; Pumera and Escarpa, 2009;
Lenshof and Laurell, 2010; Oita et al., 2010; Scheinberg
et al., 2010), so perhaps the VAC-CHIP is not so far away
after all.
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Energy, climate and environmental biotechnology
Ian M. Head, School of Civil Engineering and Geo-
sciences, Newcastle University, Newcastle upon Tyne,
UK
Meeting the needs of global development while maintain-
ing high environmental standards is a difficult balancing
act. This is more true today than at any time in human
history. China, India and Brazil, three of the five largest
countries on the planet, account for almost 40% of the
world’s population and their economies are burgeoning.
With this comes an enormous appetite for energy – and
enormous environmental impact. The empirical relation-
ship between economic growth and pollution is often
described by an environmental Kuznets curve (EKC),
named after the Nobel Prize-winning economist Simon
Kuznets who observed that the relationship between
inequality and per capita income followed an inverted U –
inequality initially increases with increasing income up
until a point where inequality begins to decrease with
further increases in income. A similar pattern is seen in the
relationship between pollution and economic prosperity.
EKCs have been observed empirically for pollution from
sulfur dioxide, nitrogen oxides, lead, pesticides, chlorof-
luorocarbons and sewage. Interestingly, this relationship
has not been observed for carbon dioxide emissions or
natural resource use. The mechanisms that cause the
inflection in EKCs are not completely understood, but the
introduction of novel technologies and legislation to drive
environmental improvements in an increasingly prosper-
ous society are usually cited as proximal reasons. Envi-
ronmental biotechnology has an important role to play in
breaking the link between economic growth and pollution
by delivering novel approaches for pollution mitigation,
and by supporting more benign energy generation and
reductions in energy use.
There is already considerable research and develop-
ment effort targeted at the production of renewable biofu-
els; however, over 80% of the world’s total primary energy
supply currently comes from fossil fuels. Even under poli-
cies to reduce CO2 emissions the International Energy
Agency estimates that fossil fuels will still meet around
70% of global energy needs by 2030. The reality therefore
is that in the short to medium term we will continue to rely
on fossil fuels to feed ever-increasing global energy
demand as current infrastructure is replaced with infra-
structure supporting more sustainable, renewable energy
sources. What therefore is the role for environmental bio-
technology in this context?
The flip side of energy production from fossil fuels is the
emission of CO2. In this respect not all fossil fuels are
equal. For example, in relation to electricity production the
US EPA has estimated that per kWh of energy produced
methane generates 0.569 kg of CO2, oil generates
0.881 kg of CO2 and coal, 0.963 kg of CO2. As we transi-
tion from fossil fuel dependence there is therefore a logic
to converting coal and oil to methane. Geochemical evi-
dence indicates that methanogenic degradation of crude
oil and coal in situ in petroleum reservoirs and coal seams
appears to be a common process. Stimulation of indig-
enous communities of methanogenic oil and coal de-
grading organisms therefore holds some potential for pro-
duction of cleaner fossil energy. Indeed such processes
are already being developed commercially and are
showing considerable promise. This approach begins to
look even more attractive given that currently achievable
recovery of light crude oil from conventional petroleum
reservoirs is around 35% and for heavy oil, which domi-
nates the world’s petroleum inventory, levels of recovery
are even poorer. By contrast around 70% of gas in place
is recoverable. Considerable technical hurdles have yet to
be overcome before energy recovery from solid and liquid
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fossil fuels as gas can become a practical solution for
biological recovery of energy assets. There has been
considerable interest in research in this area from major
energy companies who have invested in the Hydro-
carbon Recovery and Conversion wing of Synthetic Ge-
nomics (http://www.syntheticgenomics.com/what/hydro
carbonrecovery.html) and the Energy Biosciences Insti-
tute programme on Fossil Fuels Bioprocessing (http://
www.energybiosciencesinstitute.org/index.php). In addi-
tion to these high profile examples several other research
groups and companies are actively pursuing this goal.
Major investment like this holds considerable promise for
biologically assisted energy recovery becoming a reality.
Nevertheless, biology alone cannot provide all of the
answers and integration of expertise from microbial
ecology, petroleum geology and reservoir engineering will
be essential to fully realize this major environmental
biotechnology.
Environmental biotechnology not only has application in
energy recovery, but also in reducing energy use. This is
particularly pertinent to the world’s largest biotechnology
– biological wastewater treatment. In the developed world
around 1.5% of electricity consumption is used to treat
wastewater. For OECD countries this equates to over
1 ¥ 1011 kWh of electricity. Conventional activated sludge
processes consume around 0.5 kWh of energy per m3 of
wastewater treated. Over half of this energy budget is
used for aeration. It therefore follows that anaerobic pro-
cesses can significantly reduce the energy and hence
environmental costs of wastewater treatment. We are
therefore poised to see a resurgence of interest in anaero-
bic wastewater treatment systems, both conventional
anaerobic digestion where key targets will be establish-
ment of systems that operate stably even at low tempera-
tures, and systems that can more effectively treat low
strength domestic wastewaters with low residual organic
load. A place will inevitably remain for nitrifying aerobic
systems and for novel combinations of aerobic and
anaerobic systems to achieve high treatment standards
at lower energy cost. Novel microbial electrochemical
systems such as microbial fuel cells (MFCs) may also
offer a route to a reduced energy footprint of biological
wastewater treatment even if these do not generate a
single Watt of usable electrical power, simply by virtue of
the fact that they have the potential to greatly reduce
forced aeration.
In the age of synthetic biology and the astounding steps
that have been made recently in this field it is inevitable
that environmental applications of bespoke organisms
for energy recovery and pollution mitigation are being
discussed. This is an exciting prospect. It is however
worth reflecting on lessons learned from the construction
of genetically engineered organisms for environmental
applications such as pollutant degradation. This research
produced a huge and invaluable body of fundamental
knowledge on the mechanisms of pollutant degradation
and regulation of specific catabolic pathways, but did not
deliver practical solutions to environmental contamina-
tion. Specially constructed organisms may be invaluable
in controlled monoculture settings and one might argue
that with the exponential increase in the ability to dissect
and reconstruct genomes and the sophisticated data
analysis techniques of systems biology, that challenges
which were not overcome in the past can now be sur-
mounted. Understanding what makes a cell tick is one
thing, understanding how it competes effectively in the
complex milieu of the natural environment may be an
altogether greater challenge.
Microbes and food, partners in sickness and
in health
Colin Hill, Alimentary Pharmabiotic Centre and Food
Health Ireland, University College Cork, Cork, Ireland
Crystal balls usually only allow a glimpse of shapes and
shadows that require interpretation. When I gaze into the
future of food microbes in health and disease, I see a
situation in which food microbiologists develop ever more
sophisticated strategies for improving food production,
food quality, food safety and food and health, only to be
confronted by the twin spectres of ‘Regulatory Agencies’
and ‘Consumers’. Why spectres? Regulatory Agencies
are often constrained to operate legislation that may
not always based on current scientific knowledge, while
we are often told that Consumers are ‘not ready to accept’
scientific advances in food science, such as irradiation,
or genetically modified foods. I will try to use the crystal
ball to bring into focus two aspects of the relationship
between food microbes and man in which we are making
significant scientific advances, but where we need to
make equivalent strides in applying this knowledge – food
safety and food and health.
First, food safety; foodborne disease is the conse-
quence of an interaction between a food, a microbe and
the human host, in which the outcome is unpredictable.
Different individuals consuming the same amounts of
similar microbes may remain healthy, or become sick, or
even die. Regulatory Agencies rely on risk assessment
to ensure a safe food supply, and these assessments
are largely based on the numbers of microbes present
(usually defined to genus or species level), and can
seem to be based on round numbers rather than scien-
tific evidence. Existing regulatory limits of 100 Listeria
monocytogenes per gram in certain foods seem to imply
that 90 bacteria are safe, but 110 are unsafe! There is
no doubt that regulators have had an enormous impact
in reducing morbidity and mortality associated with food
in developed societies, but the problem of foodborne
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disease has not been solved. We may be reaching a
point where more sophisticated strategies will have to be
considered to reduce not only the risks associated with
foodborne pathogens, but also to decrease the waste
associated with unnecessary recalls. It is likely that a
significant amount of food is destroyed every year that
contravenes regulations, but does not really pose a
threat to the consumer. Equally, it is entirely possible
that food will cause illness and even death even though
it conforms to regulatory standards. In the future, the
level of threat to the consumer may well be defined not
only by numbers present, but also by the genotype of
the individual organism(s) in the food. Does the strain
have the necessary virulence factors to cause disease,
are those virulence factors functional? The crystal ball
predicts the use of near real-time quantitative high-
throughput microbial genotyping to define risk levels.
High-throughput mRNA analysis may even be used to
assess viability, or the level of stress adaptation of the
microbes in situ. I foresee regulations that will ‘permit’
certain levels of some pathogens, but enforce zero tol-
erance on others of the same species depending on
their genotype and thus their virulence potential. This is
obviously a complex and challenging approach to ensur-
ing food safety, but it is the logical consequence of our
increased knowledge regarding the actual virulence
potential of individual strains. In fact, this more sophis-
ticated approach has already begun. We already dis-
criminate microbes more precisely that we could have
imagined only a few short years ago. Current regulations
distinguish between Escherichia coli as indicator organ-
isms, E. coli virotypes with the potential to cause mild
foodborne disease, and verocytotoxic strains such as E.
coli O157:H7, which are recognized to pose a serious
threat to consumer health. This is already the forerunner
of a regulatory framework based on genotype rather
than genera or species.
And what does the crystal ball predict for the future of
microbes in food and health? Current regulations state
that food may not be used to prevent, treat or cure
disease, but this is surely semantics. Nutritional diseases
are specifically excluded, such as osteoporosis, beriberi,
scurvy or rickets, all of which can be addressed by diet.
So the regulations seem to suggest that while certain
diseases can be prevented, treated or cured through spe-
cific food interventions, it is not permitted to extend this list
beyond nutritional diseases. But why should regulations
constrain us from using food containing a microbe or
another functional ingredient, which has been proven to
have a positive effect in alleviating suffering? If rigorous
scientific evidence supports the efficacy of a food microbe
or ingredient in preventing the onset of a disease or in
treating an ongoing condition, why should it be prohib-
ited? Through the crystal ball I see this attitude changing
radically over the coming years, to the point where we will
look back and wonder at regulations that prevented con-
sumers from benefitting from the meticulous and exciting
scientific research in the area of food and health. I see
foods containing microbes with demonstrated benefits in
the prevention or treatment of inflammatory, atopic and
infectious diseases, and perhaps even in reducing the
incidence of devastating diseases such as colon cancer.
Looking even further ahead, I see consumers welcoming
foods containing microbes, which have been genetically
enhanced to improve their health promoting capabilities,
but always in the context of an informed risk–benefit
analysis.
Now the ball grows dim (improving battery life is
someone else’s problem), but the way forward has
become crystal clear – food developed in partnership with
regulatory agencies and consumers, which reduces the
morbidity and mortality associated with foodborne infec-
tions and their sequelae, and which also provides scien-
tifically proven health benefits by delivering a ‘payload’ of
microbes designed by nature or by science to improve the
human condition.
Opening a black box: how microbial ecology can
inform global climate models
Gary K. Jacobs and Martin Keller, Oak Ridge National
Laboratory, Oak Ridge, TN, USA
The field of biology is undergoing a revolution and is
becoming increasingly interdisciplinary. This interdiscipli-
narity is not simply in the context of sub-disciplines of
biological sciences such as physiology, biochemistry and
molecular biology but, more strikingly, among fields as
disparate as biology, chemistry, physics, mathematics and
engineering (Kalluri and Keller, 2010). The accessibility of
recent technological and conceptual innovations such
as genome sequencing, transcriptome and proteome
profiling technologies, easy to use experimental kits, high-
resolution imaging and robotics has spurred design and
fruition of many ambitious molecular characterization
experiments in the animal, plant and microbial worlds
(Kalluri and Keller, 2010). The field of microbial ecology
sees a tremendous increase in the use of these new
technologies, especially next generation sequencing
technologies to analyse complex microbial communities.
These complex environmental sequencing data enable
follow-up experiments to determine environmental RNA
profiling measurements and environmental proteome
analysis directly from complex microbial communities.
One of the bottlenecks in our current investigative
methods is in efficient generation, deposition, integration,
analysis and mining of large and diverse datasets. Cross-
disciplinary collaborations between biologists, instrument
scientists, computational modelling and statistical experts
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are needed to address this bottleneck. Data size derived
from new analytical tools such as sequencing is antici-
pated to further increase significantly during the next
years. Biology as a discipline will rely on the creation of an
integrated data storage and analysis tool, also referred as
Knowledgebase. The US Department of Energy, Office of
Science is developing a Systems Biology Knowledge-
base, envisioned as an open cyberinfrastructure to inte-
grate systems biology data, analytical software and
computational modelling tools that will be freely available
to the scientific community. This Knowledgebase will drive
two classes of work: (i) experimental design and (ii) mod-
elling and simulation (for more information see http://
genomicscience.energy.gov/compbio/).
Understanding the impacts of climate change is one
of the great challenges we are facing today. A warmer
climate will impact both terrestrial and ocean ecosystems
in ways we do not fully understand. And, there are impor-
tant feedbacks to the climate system from these ecosys-
tems as they warm and respond to higher concentrations
of atmospheric CO2. We need to understand the tightly
coupled biogeochemical cycles (carbon, nitrogen, water,
etc.) and the important drivers of those cycles that occur
at all scales of biogeochemical organization (Schimel,
2004). At the largest scale of space and time are phe-
nomena such as the ‘Great Ocean Conveyor’, which
circulates water (plus chemicals and heat) through the
oceans of the planet, spanning to the smallest scales of
organization like chemical reactions in the atmosphere
or biogeochemical dynamics in terrestrial ecosystems.
Microbial processes dominate global biogeochemistry,
accounting for roughly half of global photosynthesis
and almost all organic matter decomposition, nitrifica-
tion, denitrification and methane production (Schle-
singer, 1997). Microbial processes, however, are regularly
treated in models as a simplistic black box, although the
details of microbial physiology can have large impacts on
global biogeochemical cycles and the planet’s climate
system (Schimel, 2004).
The carbon and nitrogen cycles are especially critical to
understanding future climate change and the response
and feedbacks of terrestrial ecosystems to future changes
(Thornton et al., 2009). Terrestrial ecosystems that have
been identified to be particularly important include tropical
forests, boreal forests, peatlands and arctic permafrost.
These ecosystems contain large quantities of carbon that
if released to the atmosphere as CO2 or CH4 could provide
significant positive feedback to the climate system and
exacerbate global warming. Boreal forests, peatlands and
permafrost hold a tremendous quantity of the Earth’s
buried soil carbon and are especially vulnerable by being
in the high latitudes where warming will be highest. In
permafrost, the seasonally thawing active layer comprises
the top centimetres to meters of permafrost soil and
accounts for most of the tundra’s biological activity
and Green House Gas (GHG) releases. Current climate
models predict a significant increase in thawing depths
and durations of thawing, turning permafrost land into
wetlands or thermokarsts where microorganisms can
mineralize complex organic matter and release CO2 and
CH4 as well as N2O and other GHG (Zimov et al., 2006;
Elberling et al., 2010). Models simulating current GHG
production and transport do not yet adequately address
permafrost thawing as a result of global warming,
changes to above-ground vegetation, or microbial miner-
alization of buried carbon.
Climate change scientists have conducted field experi-
ments, often at large scale, to see how ecosystems will
respond to more or less precipitation, rising concentra-
tions of atmospheric carbon dioxide and warming tem-
peratures. Experimental data are key to determining if and
to what extent ecosystems will be affected by climate
change in 50 to 100 years and how those changes might
feed back to further advance change (Wullschleger and
Strahl, 2010).
Two next-generation ecosystem experiments are being
planned for deployment that will shed light on these
important processes. An experiment to expose a boreal
forest – peat bog ecosystem in Grand Rapids, MN, USA
to both warmer temperatures and elevated CO2 concen-
trations is under development using an innovative com-
bination of belowground and aboveground warming tech-
nology (see Fig. 1) while also enriching the CO2 concen-
tration in the atmosphere around the forest (Hanson et al.,
2010). A second experiment is being considered
for implementation in the permafrost in Alaska, USA
(S.D. Wullschleger, pers. comm.). Both of these experi-
Fig. 1. A prototype warming chamber constructed at Oak Ridge
National Laboratory that is being tested for refinement before
deployment for an ecosystem manipulation experiment
in a spruce – peat bog near Grand Rapids, MN, USA
(https://mnspruce.ornl.gov/). Photo compliments of Paul Hanson,
Oak Ridge National Laboratory.
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ments will provide critical large-scale process understand-
ing to improve earth system models. But, they also offer
unique opportunities for microbiologists to collaborate
with plant biologists, ecologists and geologists. The sci-
entific opportunities to explore biogeochemical cycles at
multiple scales with modern biological, chemical and
physical methods is unprecedented and will challenge us
to develop new informatic tools to integrate these new
data that span disciplines and scales. With these integra-
tive studies we may begin to open up the proverbial black
box and quantify important interfacial and molecular bio-
geochemical processes.
References
Elberling, B., Christiansen, H.H., and Hansen, B.U. (2010)
High nitrous oxide production from thawing permafrost. Nat
Geosci 3: 332–335.
Hanson, P.J., Childs, K.W., Wullschleger, S.D., Riggs, J.S.,
Thomas, W.K., Todd, D.E., and Warren, J.M. (2010) A
method for experimental heating of intact soil profiles for
application to climate change experiments. Global Change
Biol 17: 1083–1096.
Kalluri, U.C., and Keller, M. (2010) Bioenergy research: a
new paradigm in multidisciplinary research. J R Soc Inter-
face 7: 1391–1401.
Schimel, J. (2004) Playing scales in the methane cycle: from
microbial ecology to the globe. Proc Natl Acad Sci USA
101: 12400–12401.
Schlesinger, W.H. (1997) Biogeochemistry. Geotimes 42: 44.
Thornton, P.E., Doney, S.C., Lindsay, K., Moore, J.K.,
Mahowald, N., Randerson, J.T., et al. (2009) Carbon-
nitrogen interactions regulate climate-carbon cycle
feedbacks: results from an atmosphere-ocean general
circulation model. Biogeosciences 6: 2099–2120.
Wullschleger, S.D., and Strahl, M. (2010) Climate change: a
controlled experiment. Sci Am 302: 78–83.
Zimov, S.A., Schuur, E.A.G., and Chapin, F.S. (2006) Perma-
frost and the global carbon budget. Science 312: 1612–
1613.
Metabolic engineering, systems biology and
synthetic biology
Sang Yup Lee, Department of Chemical and Biomolecular
Engineering, KAIST, Daejeon, South Korea
In the sunny morning of November 15, 2017, Professor
Meteng is having a conversation with one of his gradu-
ate students in the lab. ‘Have a look at this. I just fin-
ished designing the 3.5 kb bacterial genome for
polyethylene terephthalate (PET) production. Wow, it
took us 2 weeks to design this sequence using our in
silico MetabolicRegulatorySignaling Designer program.
As we discussed, we now optimally positioned all the
genes necessary for cell growth and PET production
from carbon dioxide and sunlight. We should be able to
produce PET with a productivity of 5.5 g l-1 h-1 and 95%
of the maximum theoretical yield. We still need to run
several fermentations to confirm the in silico predicted
performance and collect data in order to further improve
this bug’s performance by fixing its genome. Once these
are all done, I expect that the production cost of this
bio-based PET will be about 2.5$ per kg. Later today, I
will send this synthetic genome sequence to the
National Genetically Created Organisms Committee for
approval to synthesize. It usually takes five working days
to get approval. Then, I will send the sequence to
company X to synthesize it. The synthetic genome will
cost $500 and will be delivered to you within 24 h. We
might get some discount as we already synthesized two
genomes last week. Once you receive the synthesized
genome, you can create PET producer using the in vitro
CELL CREATOR kit we purchased last week. How do
we want to name this bacterium? Hmm . . . how about
Plasticomonas superproduciens KAIST2017?’
Over the last couple of decades, metabolic engineer-
ing (Bailey, 1991) has advanced rapidly to design and
develop engineered bacteria in order to more efficiently
produce drugs, chemicals, fuel and materials. Tradi-
tional metabolic engineering started by manipulation of a
handful of genes to be amplified, deleted, and/or intro-
duced heterologously. Over the last decade, advances in
systems biology have changed the way metabolic engi-
neering is performed. Based on the rapid analysis of
the entire genome followed by other omics studies
including transcroptomics, proteomics, metabolomics
and even fluxomics, metabolic engineers are now
equipped with vast amounts of data and simulation tools
that can be used in designing the optimally performing
cells. A system-wide analysis and engineering of meta-
bolic and other cellular networks are now possible – and
thus called, systems metabolic engineering (Lee et al.,
2007). More recent advances in cost-effective DNA syn-
thesis and synthetic biology are triggering our interest in
possibly designing the whole genome followed by actual
genome synthesis. Although Craig Venter’s the first arti-
ficially synthesized genome (Gibson et al., 2010) is far
away from the creation of true ‘designed cell doing
something useful’, it showed the possibility for the first
time.
Are we really interested in creating artificial organisms,
such as overproducers of biofuel, plastics, chemicals
and drugs? The answer is YES; but first, we might want to
define what artificial organisms are. If we start with our
favourite microbe E. coli, and engineer it by knocking out
50 genes, amplifying 10 genes, altering 7 regulatory cir-
cuits, and introducing 10 heterologous genes originated
from plants and animals, is the resulting strain an engi-
neered E. coli or created artificial cell? What if the number
of genes that are altered reaches over 50% of the original
genome? What do we call it? One thing for sure is that this
120 Crystal ball
© 2011 The Authors
Journal compilation © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd, Microbial Biotechnology, 4, 109–137
type of engineering (or creation) should be performed for
the benefits of human and environment. Ethics, safety
and security issues will become increasingly important
(Lee, 2010).
Metabolic engineering is an essential paradigm for
the environmentally friendly production of chemicals and
materials from renewable resources with an aim to save
our earth and sustain human race, and developing ways
of efficiently producing drugs that are new or difficult
to synthesize. Innovative ways of bioremediation using
metabolically engineered organisms will also be devel-
oped. Looking ahead, it is likely that many sophisticated
organisms developed by systems metabolic engineering
will appear over the next 7 years, mainly for the enhanced
production of drugs, chemicals, fuels and materials. Some
of these will be incorporated into the actual industrial
biorefinery processes for the mass production. At the
same time, organisms that are based on 100% synthe-
sized genomes will continuously appear; the first handful
of these will be most likely mimicking the genomes of the
organisms already present in nature. We should not think
that we are playing God.
It is also likely that systems metabolic engineering
approaches will be adapted to new therapeutics and
disease prevention. Human body (and other organisms as
well) is a truly complex system, which will almost never be
completely understood. Our current therapeutic paradigm
is a single drug-single target approach, while multiple
drugs (a mixture of single drugs) can be administered to
treat multiple respective symptoms. An old Korean saying
‘the best drug is good food’ deserves good attention. The
traditional Korean medicine book ‘Dong-Eui-Bo-Gam’
written by Hur Jun 400 years describes many interesting
therapeutic recipes for treating chronic diseases. Obvi-
ously, millions of secondary metabolites among others
present in these mixed plant extracts cannot be consid-
ered as drugs in the current drug administration stan-
dards. If multicomponent multi-target interactions are
clarified at the systems level, and designer plant combi-
nations without side-effects can be formulated, it will
change the human healthcare paradigm – to this end,
systems metabolic engineering will play an important role.
Ultimately, what we eat (food) will be systematically
coupled to our health issues through systems nutrition,
and for this, the approaches developed in systems meta-
bolic engineering field will become essential.
References
Bailey, J.E. (1991) Toward a science of metabolic engineer-
ing. Science 252: 1668–1675.
Gibson, D.G., Glass, J.I., Lartigue, C., Noskov, V.N., Chuang,
R.-Y., Algire, M.A., et al. (2010) Creation of a bacterial cell
controlled by a chemically synthesized genome. Science
329: 52–56.
Lee, K.H., Park, J.H., Kim, T.Y., Kim, H.U., and Lee, S.Y.
(2007) Systems metabolic engineering of Escherichia coli
for L-threonine production. Mol Syst Biol 3: 1–8.
Lee, S.Y. (2010) Editorial: a call for ethical regulation of
Genetically Created Organisms (GCOs) beyond GMOs.
Biotechnol J 5: 791.
Bioprocess Systems Engineering: bridging the
‘scales’ between ‘molecules, cells & processes’
Athanasios Mantalaris, Biological Systems Engineering
Laboratory, Department of Chemical Engineering, Impe-
rial College London, London, UK
Mathematical models of biological systems developed
over the last decades incorporate various degrees of
structure and mathematical complexity. Focusing on
microbial systems, models of single cells, cell populations
and cultures have been central in the understanding and
improvement of the cellular systems, as well as in the
optimization and control of the bioprocesses (Thilakavathi
et al., 2007). In the last decade especially, the large-scale
generation of biological data obtained with the develop-
ment of a variety of high-throughput experimental tech-
nologies enabling system-level measurements, demand
for mathematical model building to become a centre of
importance in biology (Covert et al., 2001). Alas, as Bailey
(1998) argued the development of mathematically and
computationally orientated research has failed to catch
up with the recent developments in biology. The need
to bridge this widening gap between mathematically ori-
ented research and system-wide analytical experimenta-
tion (‘omics’ technologies) stimulated Systems Biology to
emerge as a new and dominant science (Bruggeman and
Westerhoff, 2007). Consequently, the logical question is
being raised of whether Systems Biology has simply
rushed into the development of new biological theories in
the quest to convert data into knowledge? In a field now
shifting from method development to application develop-
ment (Oberhardt et al., 2009), there is now some increas-
ing scepticism regarding the future of Systems Biology as
understanding of all the collected information has lagged
far behind its accumulation because modelling of complex
systems is an inverse problem that cannot be solved
(Brenner, 2010).
Simply put, even relatively simple microorganisms,
which have been extensively studied, are hosts to a
complex network of interconnected processes occurring
on diverse time scales within a confined volume. The
multilevel nature of the regulatory network and the inter-
actions occurring at the intracellular level further augment
this complexity (Yokobayashi et al., 2003). Therefore,
attempts to wholly model the function of even a single cell
are non-trivial, if not impossible. The amount of delicate
intracellular measurements required to validate such a
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model is exhaustive both in terms of labour as well as
cost, even with the arsenal of the ‘omics’ technologies
at hand. Furthermore, uncertainties introduced on the
parameter identifiability level (Sidoli et al., 2003) and on
the mechanistic level further complicate this task. The
balancing point for the trade-off between fidelity and trac-
tability is a constant concern even with the advancements
in both numerical tools and raw computational power. A
thorough overview of the literature reveals that the optimal
point on the scale between tractability and fidelity does
not lie near the boundaries. What ultimately discriminates
a good model from a bad model is its ability to success-
fully describe the modelled process while minimizing the
uncertainty of its output variables. However, in the major-
ity of studies the most common approaches followed are
either utilization of literature data to validate the models or
generation of experimental data without any form of sys-
tematic design of experiments. From an engineering point
of view, this information can only be utilized through a
systematic and rigorous framework that will organize and
prioritize necessary measurements and experiments
while simultaneously maximizing information obtainable
from the data (Sidoli et al. 2004).
The ever-increasing development and improvement of
sustainable bioprocesses towards efficient production of
pharmaceuticals and chemicals inadvertedly requires
the implementation of a rational and feasible approach.
Process systems engineering offers a variety of model-
ling, simulation and process evaluation tools, which are
widely used in the chemicals and fuels sectors where
even small process improvements may bring substantial
economic profits (Jimenez-Gonzalez and Woodley,
2010). Therefore, the need for a Bioprocess Systems
Engineering research framework may prove beneficial.
We have formalized such a systematic approach for mod-
elling biological systems (Kontoravdi et al., 2005; 2007;
2010; Kiparissides et al., 2009; Koutinas et al., 2010),
shown in Fig. 2. In our opinion, a mathematical represen-
tation of a studied biological system should aim to
describe the system using adequate yet not excessive
information regarding the relevant biological mecha-
nisms. Overly complex mathematical formulations that
lead to over-parameterized models should be avoided.
Rigorous model analysis is required to screen for signifi-
cant and/or redundant parameters and design optimally
informative experiments in order to refine the parameter
values and minimize the uncertainty in the model output
even potentially leading to model reduction. The aim
should be a ‘high-fidelity’ model that is successful over a
wide range of operating conditions that can be used for
model based optimization and control. Maybe then we
can successfully bridge ‘scales’ between ‘molecules, cells
& processes’ that will render modelling practically useful
to biology.
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Microbes watching over us
Jan Roelof van der Meer, Department of Fundamental
Microbiology, University of Lausanne, Lausanne,
Switzerland
Foretelling the future is a rare gift privileged to very few
among us. Luckily, some things appear so crystal clear
that even a lay oracle as myself can make reasonable
guesses as to their future developments. For the sake of
this crystal ball worth concentrating upon is the foresee-
able lack of clean primary resources and the need for
increased resource recycling and monitoring in an ever-
increasing demanding and populated society. In particular
the availability of clean water is of growing concern,
given the wide variety of direct and indirect water usages
(Gleick and Palaniappan, 2010). Although water is in prin-
ciple a renewable resource at a global scale, strong
regional differences of water use and availability (flux)
lead to non-renewable and unsustainable use (Gleick and
Palaniappan, 2010). In addition, used water streams
are often (severely) contaminated, and this precludes
recycling on a regional scale unless appropriate phy-
sicochemical and or biological treatment systems are
installed. Our discipline can praise itself for its past
accomplishments to understand, develop and apply
microbial activity-based processes that help recycling
organic waste streams, purify water, recover nutrients or
improve hygienic aspects of water supply. Unfortunately,
many existing effective treatment processes (e.g. biologi-
cal wastewater treatment) are not implemented in large
areas of the World, exacerbating the degradation of water
quality in those areas and, as a consequence, depleting
local water sources and fluxes. Even without new future
process developments, therefore, much could already be
improved by implementing existing microbiological treat-
ment processes.
Constant recycling of used water at a small regional
scale, as, for example, typical in European river basins,
not only demands excellent purification and treatment
technology, but also a rigorous implementation of quality
monitoring, both at the ‘source’ and the ‘waste’ level. This
is typically done by well-equipped analytical labs, but
even so, constantly appearing new compounds of toxico-
logical concern (e.g. pharmaceuticals) demand continued
efforts in analytical developments. Other areas of the
World are characterized by decentralized water supplies,
even at the level of individual households (Fendorf et al.,
2010), in which case quality control is not trivial, not even
for compounds that we consider ‘standard’ in western
countries (e.g. heavy metals). In order, therefore, to
increase the potential for water recycling at a regional
scale, appropriate purification technologies and effective
monitoring methods have to go together. So what can
microbial biotechnology contribute to those aspects?
Here I would only like to concentrate on the ‘monitoring’
aspect, which has seen a steady development of the
concept of bioreporter assays over the past 15 years or so
(van der Meer and Belkin, 2010). Bioreporter assays
implement living cells (prokaryotes, yeasts, other types of
cell lines) as analytical tools. The idea behind bioreporter
assays is to exploit the capacity of every cell to sense the
presence of chemical compounds in and outside the
cellular compartment. Chemical sensing by cells is
performed by membrane receptors with specific ligand-
binding domains or by cytoplasmic regulatory proteins,
that can relay effector binding to de novo gene expres-
sion. In bioreporter cells, the cognate signal cascade
is replaced by a gene circuit in which activation of
the sensory protein results in expression of a so-called
reporter gene, such as luciferase or an autofluorescent
protein. Use of such non-native reporter proteins enables
to measure reactions of cells very sensitively, non-
invasively and at low concentrations of chemical com-
pounds. Bioreporter technology can thus be used to
produce cheap and robust biological assays to measure
the presence of a variety of chemical compounds. Pres-
ently, two categories of systems have been produced;
those, which target specific chemical compound classes,
and, second, those, which target any compound that
exerts ‘toxicity’ or ‘stress’ to the cell (van der Meer and
Belkin, 2010). Bioreporter assays come in various assays,
and currently permit easy and sensitive measurement of
compounds not only in aqueous samples, but also food
stuffs, other solid materials, biological fluids or in the gas
phase. Bioreporter assays have been extensively tested
in numerous different laboratories, in environmental set-
tings and in comparison with chemical analytics, and this
has demonstrated that the technology is ‘ripe’ and can be
applied at various levels of complexity.
What is then my wish list for future developments in this
area? I hope that the technology will reach a ‘legal’ break-
through in the sense of becoming recognized as official
test in OECD procedures. This would help enormously in
implementing bioreporter tests to standard analytical labs
and propose them as realistic alternatives in areas where
chemical analytics is too expensive or unavailable. Biore-
porter engineering is also one of the very concrete
applications of synthetic biology, where gene circuits with
different biological parts are assembled into workable
bioreporter strains. There are many examples of how
more and better parts would be useful for bioreporter
technology. For example, it would be extremely valuable
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to have more sensory proteins with different chemical
recognition specificities. This will require efforts to
combine protein structure information, genome searches
for homologous proteins, and directed evolution
approaches, in order to more reliably design sensory pro-
teins ‘à la carte’. Synthetic biology will also help to under-
stand how to build new types of reporter circuits with
signal amplification procedures or reduced background.
Finally, bioreporter technology will profit enormously from
a true integration with micro-engineering (van der Meer
and Belkin, 2010). Because of their small size, bacterial
and yeast reporter cells can be easily integrated on
microfluidics platforms, where the cells can potentially
be cultured and their signal followed continuously. An
integration into microfluidics platforms may also permit the
development of true reporter arrays, by which a multitude
of strains equipped with different sensing specificities can
be confined each to an individual small area on one plat-
form. This would enable measuring multiple target com-
pounds simultaneously.
Microbes watching over the quality of our primary
resources; who would have thought this?
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Model guided engineering of microbial
metabolism
Jens Nielsen, Department of Chemical and Biological
Engineering, Chalmers University of Technology, Gothen-
burg, Sweden
In recent years there has been a rapid growth in the
development of genome-scale metabolic models for dif-
ferent microorganisms. These models are traditionally
reconstructed through a bottom-up approach, where
genomic information is combined with information from
databases and the literature to establish a list of biochemi-
cal reactions that can take place in the organism under
study. The resulting metabolic network is then undergoing
further analysis, where gaps in the different metabolic
pathways are filled, either through further search in the
genome or simply by inferring the specific enzymatic func-
tion that will ensure gap closure. The resulting, gap-free,
metabolic network can then be used for simulation of
metabolic functions through the use of flux balance analy-
sis. This allows for rapid evaluation of the metabolic capa-
bilities of the microorganism studied, and this allows for
evaluation of different metabolic engineering strategies,
e.g. what is the impact of deleting specific genes and what
is the impact of inserting specific genes on the microor-
ganisms ability to produce a desirable metabolite. There
have already been described several successful applica-
tion of genome-scale metabolic models for identification
of metabolic engineering targets, and clearly the future
will bring many further examples.
However, to further advance the use of genome-scale
metabolic models in metabolic engineering two things
will be required: (i) a faster route for constructing and/or
updating these models and (ii) better description of meta-
bolic regulation. The first will require better integration of
model building/revision with databases, such that new
annotations can rapidly be integrated into the models
and hence improve their performance. This will require
bridging between genomics, bioinformatics and metabolic
modelling. The second will require integration of regula-
tory information into genome-scale metabolic models.
Even though there is progress on incorporation of ther-
modynamics into these models, and some initial work has
been done on including regulation in a few models, still
much more is needed to advance the predictive strength
of genome-scale metabolic models. However, I am certain
that within the next 3–5 years we will have seen substan-
tial progress in this field, and will be presented with meta-
bolic models that are better integrated with genomics
databases and that incorporate extensive regulation. This
progress will be pioneered by work on the bacterium
Escherichia coli and the yeast Saccharomyces cerevi-
siae, which besides serving as model organisms also
serves as important industrial cell factories.
Microbial ecology and water engineering
Per Halkjær Nielsen, Department of Biotechnology,
Chemistry and Environmental Engineering, Aalborg Uni-
versity, Aalborg, Denmark
We have a ‘Specialist Group’ in the International Water
Association named ‘microbial ecology and water engi-
neering’ and I have borrowed this title for my look into
the crystal ball. Both because the topic is extremely
important for the big challenges facing the rapidly
growing human population in treating wastewater and
providing drinking water – but more importantly because
a paradigm shift is currently underway in our under-
standing of microbial communities in the context of
water engineering and thus Environmental or Microbial
Biotechnology. When I look in the crystal ball I’m,
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however, not sure whether it is mainly a ‘I believe’ or ‘I
hope’ – but perhaps it is both as described below.
The future of microbial ecology will provide many excit-
ing things to the engineers and – what many tend to forget
– also visa versa: New microbial processes have in the
past been discovered in engineered systems, e.g. the
process for removal of the nitrogen by anaerobic ammo-
nium oxidation (anammox) and enhanced biological
removal of phosphorus. In case of the anammox organ-
isms, they proved not just to be important in engineered
systems, but central to the whole global N-cycle. The next
decade will undoubtedly reveal several new organisms or
microbial consortia that can be developed into useful full-
scale processes in water and wastewater treatment or in
the recovery and reuse of non-renewable recourses, such
as phosphorus and production of bioplastic.
In order to manage the microbial ecosystems, microbial
ecology needs to provide engineers with better models
and theories about how these complex ecosystems work.
Many wastewater treatment plants are still run as a ‘black
box’ with a minimum of knowledge about the functioning
ecosystem that lies behind. In the not too distant future I
see the development of representative ‘model ecosys-
tems’ where a detailed understanding of the underlying
organization of the ecosystem has been obtained. Bill
Sloan and Tom Curtis have initiated to incorporate the
huge microbial diversity into relatively simple models that
take the first steps at elucidating the general rules for the
assembly of microbial ecosystems (Ofitery et al., 2010). I
see a further development of such ‘top down’ models and
a meeting of these with the deterministic ‘bottom up’ meta-
bolic models and mass transfer models, e.g. by advanced
3-D biofilm models as developed by Cristian Picioreanu
and Mark van Loosdrecht (Graf von der Schulenburg
et al., 2009). It will be interesting to see these approaches
merge in the future.
Metagenomics and other ‘–omics’ methods are
extremely useful to obtain lots of information about spe-
cific ecosystems. The number of studies of engineered
systems – although is still few – have given invaluable
new knowledge, but have mainly been limited to the
sequencing of genomes of uncultured organisms such as
the anammox bacteria, polyphosphate-accumulating
organisms and nitrifiers obtained from highly enriched
cultures. Metagenomes of entire model ecosystems
will characterize the diversity and potential function of
the entire community and are now becoming practically
possible because of rapidly improving sequencing and
bioinformatics capacity. A deeper understanding of eco-
systems must combine these approaches with transfor-
mation rates to characterize the overall function of the
system. These advances will be combined with advances
in single cell techniques that link the genomic informa-
tion with species-related morphology, surface properties,
3-D organization in the aggregates and other func-
tional details. The combination of ‘-omics’ with single-cell
studies is extremely important – just ask a plant operator
where the entire treatment plant is covered by a thick
foam layer caused by a certain filamentous bacterium
excreting hydrophobic surface components! My crystal
ball sees these studies eventually developing an easy and
fast community fingerprint of structure and function that
contains both a diagnosis of problems and suggestions
for corrective actions of relevance for the operation of
the system.
Is the microbial diversity in engineered systems so high
that it is beyond our reach to cope with? Fortunately, not
so! We have been studying in a large number of Danish
wastewater treatment plants with enhanced biological
phosphorus removal and discovered a surprising similar
composition of the microbial communities (Nielsen et al.,
2010). However, indications are strong that the microdi-
versity among the different species or genera is very large
in the individual plants and perhaps partly decisive for
plant function and stability – which should be resolved in
near future.
The exciting new microbial ecology and ‘Systems
Biology’ will go hand in hand with the next generation
of ecosystem theories and modelling and – not to forget –
the developing of new technologies in water engineering.
This will require more co-ordination and cross-disciplinary
collaboration – already at the university and during post-
graduate training. Strangely, this aspect of the future is –
in my crystal ball – still unclear. I certainly hope that this
wish will also come true.
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Switch on the bugs! (Where Environmental
Engineering meets Synthetic Biology)
Korneel Rabaey, Advanced Water Management Centre,
The University of Queensland, Brisbane, QLD, Australia
Microbial respiration is a form of internal electricity gen-
eration. In 1962 Davis and Yarbrough elegantly exploited
this in the first true MFC: electrical power was produced
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from organic conversion and sunlight (Davis and
Yarbrough, 1962). In 1979 the process was reversed,
electricity was given to a fermenting organism and its
product spectrum changed (Hongo and Iwahara, 1979).
While MFCs resurfaced strongly in the past years, we now
know that effective power production at scale is challeng-
ing, and that the economic and environmental drivers for
this bioelectricity are limited. Aside from developing
advanced bioremediation approaches, many researchers
are now refocusing towards the production of chemicals
and fuels with this technology (‘bioelectrochemical
systems’). Electrical current can indeed be used to drive
microbial metabolism for bioproduction, by changing the
outcome of fermentation, or by driving respiration (‘micro-
bial electrosynthesis’) (Nevin et al., 2010; Rabaey and
Rozendal, 2010).
Producing (bio)chemicals starting from electricity and
CO2 or substrate organics could have many advantages,
such as high-production density, CO2 capture, facilitated
storage and ‘transport’ of electricity. Particularly attractive
is the combination with wastewater. Although its supply is
limited and localized, wastewater organics can provide an
energy-efficient source of the electrical current and CO2
(anode), while the wastewater nutrients can support the
growth of producing organisms (present at the cathode).
Principally, microbial electrosynthesis uses microorgan-
isms to convert mixed organics into electrical current, and
converts electrical current into specific organics of inter-
est. Biorefining in one reactor!
What is needed to make this work is a good technol-
ogy platform (including electrode materials), microbial
populations to degrade the wastewater organics and
effective production strains to convert the electrical
current into the desired product. We have none of these
today. This is hence where environmental engineering
meets synthetic biology. Breakthroughs are needed to
create biocompatible, low-cost electrode materials, com-
bining surface area with surface charge and functional-
ity. We need to engineer microorganisms that effectively
produce biochemicals using electrical current as electron
donor. And, we need to develop a technology that brings
this process to scale, in a wastewater context or in a
straight bioproduction context. Quite some walls
between microbiologists and engineers need to be torn
down, and the challenging creation of a common lan-
guage will be part of this.
If we succeed, we will extract sufficient value from
wastewater to turn it from a waste into a resource, with
a positive value. Wastewater treatment can thus be pro-
fessionalized to the level of true biorefining, where
water, organics/energy and nutrients are extracted and
brought back to the market. Outside the wastewater
context, the sun can (via photovoltaics) drive microbial
electrosynthesis, and thus enable bioproduction in areas
that are not suitable for agriculture. Areas such as the
Australian outback and the Arizona desert suddenly
provide a tremendous opportunity for large-scale biore-
fining. So if all goes well, you may find that someday
your wastewater will go to the highest bidder, and that
you can fuel your car not only in the Saudi-Arabian
desert . . .
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Giving a little help to our prokaryote friends
Bruce E. Rittmann, Center for Environmental Biotechnol-
ogy, Biodesign Institute at Arizona State University,
Tempe, AZ, USA
Because of their small size and simple physiology,
prokaryotes are especially capable of exploiting an amaz-
ingly wide range of metabolic niches that also provide
wonderful services to society. I illustrate the amazing
variety by giving a few examples of prokaryotic physiolo-
gies that are relatively recent discoveries and that hold
promise for providing important services:
• Certain bacteria are able to carry out respiration via
extracellular electron transport through a conductive
biofilm matrix (Torres et al., 2010). These anode-
respiring bacteria offer promise for producing renew-
able electricity, hydrogen gas and other materials from
biomass organics.
• Species of Dehalococcoides are able to reductively
dechlorinate organic solvents, such as trichloroethene,
to harmless end-products in another unique form of
respiration (Löffler et al., 2005). Dehalococcoides
already are being used commercially for bioremediation
of solvent-contaminated sites.
• The ANAMMOX planktomycete is able to oxidize
ammonium while respiring nitrite, creating a novel form
of anaerobic ammonium oxidation (Strous et al., 1999).
This startling discovery is being pursued for the treat-
ment of high-ammonium waste streams (Van Loos-
drecht et al., 2004).
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High-value services for pollution abatement and
renewable energy/materials also can be obtained by
exploiting ‘mundane’ microorganisms, such as methano-
genic Archaea to produce renewable methane (Speece,
2008), ammonia- and nitrite-oxidizing bacteria to eliminate
ammonium pollution (Siripong and Rittmann, 2007), and
hydrogen-oxidizing autotrophs to reduce nitrate, perchlo-
rate, and a range of other oxidized contaminants (Ritt-
mann, 2007).
Whether the microorganisms are novel or mundane,
sometimes they need a ‘bit of help’ so that they can
sustain themselves as they provide society with its
service. This help can take different forms – biological,
physical or chemical. Examples of help are increasing
their metabolic capability, making their substrates more
available, protecting them from toxicity, and retaining
them in a favourable location. Cleverly applying the right
kind of help will become more and more important as
environmental biotechnologists strive to gain more ser-
vices from the microbial communities.
One biological approach involves modestly redirecting
the metabolism of a well-suited microorganism so that it
provides the service that society desires. This approach is
sometimes called metabolic engineering (Stephanopo-
ulos et al., 1998), and it differs from ‘synthetic biology’
approaches that attempt to construct cells de novo
(Chopra and Kamma, 2006). The likelihood of success is
greatly increased when the added metabolic functions
expand the capability of a microorganism that flourishes in
the conditions required to provide the service. My col-
leagues Willem Vermaas and Roy Curtiss are taking
this approach to direct the metabolism of the cyanobac-
terium Synechocystis PCC6803 to produce and excrete
long-chain fatty acids that are harvested directly from the
reactor medium; the fatty acids then become a renew-
able feedstock to make liquid transportation fuels. This
approach exploits a robust phototrophic bacterium and
eliminates the need to harvest biomass and extract lipids
from the biomass. Vermaas and Curtiss achieve their goal
by adding genes for enzymes that produce the fatty acids,
while also deleting genes for enzymes that consume the
fatty acids. If ultimately successful, this metabolic help will
allow PCC6803 to absorb sunlight energy and fix CO2 into
a renewable petroleum replacement, making PCC6803 a
true photosynthetic factory. Thus, PCC603 remains a pho-
totroph, and we help it produce our desired product, long-
chain fatty acids.
A form of physical help that has widespread applicability
for generating renewable energy from biomass involves
pretreating the biomass to make it more bioavailable for
conversion to methane, hydrogen, or other energy forms
by anaerobic microbial communities (Rittmann, 2008).
Several biomass-treatment technologies are now com-
mercially available to disrupt biomass aggregates and
cells to make them more bioavailable (Salerno et al.,
2009): e.g. mechanical shearing, ultrasound, heating,
freezing, and exposure to pulsed electric fields. The
anaerobic communities still ferment and respire in ways
that produce valuable energy outputs, such as methane
or hydrogen gases, but pretreatment helps them do it
faster and more completely (Rittmann et al., 2008;
Salerno et al., 2009).
Providing our prokaryote friends with a bit of help
follows the basic principle of environmental biotechnology
(Rittmann, 2006): ‘We work for the microorganisms so
that they work for us.’
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Bacteria and nanoscale biophysics
Alejandro V. Silhanek, Institute of Nanoscale Physics and
Chemistry (INPAC), Department of Physics and
Astronomy, Katholieke Universiteit Leuven, Flanders,
Belgium
Jos Vanderleyden, Centre of Microbial and Plant Genet-
ics, Department of Microbial and Molecular Systems,
Katholieke Universiteit Leuven, Flanders, Belgium
Small is beautiful. During the last years we have wit-
nessed a spectacular breakthrough in the design and
fabrication of tailor made artificial templates or meta-
materials at the nanoscale with outstanding properties.
This is a direct product of the nanotechnology revolution
that has permitted superior performance first on electronic
devices, microelectromechanical systems, and more
recently in the manipulation and confinement of light. The
main idea behind structuring materials down to dimen-
sions matching the characteristic sizes of the elementary
blocks (i.e. electrons in metals, photons and plasmons in
lights, or fluxons in superconductors) is that boundary
conditions become more relevant and lead to pronounced
modifications of the general response of the system. In
physics, the most popular example is the emergence of
the discrete character of nature, the so-called quantum
limit, once we reach this nanoscale realm.
The curiosity for exploring the effects of spatial confine-
ment and the importance of the scale is currently also
taking a leading role in the world of microbes. This was
already anticipated in the previous Crystal ball edition
back in 2007 by Les Dethlefsen and Relman (2007). This
novel research line lies at the crossroads of several dis-
ciplines such as nanoengineering of microfluids, lab-on-
a-chip technology, modern nanofabrication techniques,
chemistry, physics and microbiology. Therefore, to guar-
antee a successful development of this colossal task, it is
imperative to achieve a mature scientific synergy among
this rich diversity of fields.
Nowadays, in almost every modestly equipped labora-
tory across the world, submicrometer patterning of mate-
rials that allows one to easily prepare small habitats
matching the dimensions of bacteria can be routinely
achieved. This has permitted Männik and co-workers
(Männik et al., 2009) to investigate the effects of sub-
micron constrictions on the motility of bacteria revealing
their previously unexpected skills to survive and prolifer-
ate in this environment at expenses of shape adaptation.
Interestingly, a major difference in shape adaptation of
Escherichia coli and Bacillus subtilis is observed, likely
related to their differences in cell wall architecture. Scan-
ning probe microscopy techniques providing information
about the nanoscale surface architecture of living cells
can reveal what exactly is going on at the cell surface
(Dupres et al., 2010). So far, it is not known how this
information of spatial confinement is processed by the
bacteria. Is the adaptation the result of physiology or
mutation? Understanding the adaptation of bacteria to
such extreme situations might have a direct and immedi-
ate impact on soil microbiology, behaviour of bacteria in
tissues and biofilms, water filtering systems and biomedi-
cal research. At these scales, not only the dimensions of
the constrictions become relevant but also their particular
shape. For instance, asymmetric funnel shaped barriers
can lead to rectification or biased bacterial motion permit-
ting one to control their concentration (Galajda et al.,
2007), or can be used to sort mixed population of cells into
different reservoirs (Mahmud et al., 2009). The use of
nano-fabricated habitat landscapes is also very promising
for the study of population dynamics of competing bacte-
ria in shared spaces (Keymer et al., 2008). We are at the
dawn of a new era striving to better understand and steer
the behaviour of bacteria in small numbers or even at the
single cell level via nanotemplates.
We can envisage further progress for instance by
taming the behaviour of magnetotactic bacteria via ferro-
magnetic templates, designing bacterio-fobic asymmetric
porous materials of practical use for medical implants, or
even to exploit the recent achievements in the control of
light at nanoscales (plasmonics) to guide or trap photo-
sensitive bacteria. An interesting question that can be also
tackled by nanoengineering surfaces is whether bacteria
are sensitive to different degrees of wall roughness.
Another fascinating concept recently posed and demon-
strated by Di Leonardo and colleagues (2010) is the
possibility to harvest the cooperative work of bacteria to
power micromachines. Although the nanofabrication tech-
nology has reached an impressive level of development,
still three-dimensional architecture will be needed to cope
with the most ambitious designs of bacterial habitats.
It is worth noting that the designs used to control the
motion of inert objects such as superconducting vortices,
colloids or magnetic beads, are very similar to those
tested in the world of small self-propelled bacteria. This
direct mapping between apparently disconnected disci-
plines guarantees a much faster development of the
research, cross fertilization of ideas and an overall huge
impact far beyond the limits of microbiology. It is clear that
the synergy and combined interdisciplinary effort will
nourish each individual part with refreshing ideas, alter-
native approaches and viewpoints.
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Synthetic enzymes: catalysis on demand
Blake A. Simmons, Biofuels and Biomaterials Science
and Technology, Sandia National Laboratories, Liver-
more, CA, USA and Deconstruction Division, Joint BioEn-
ergy Institute, Emeryville, CA, USA
Enzymes are versatile, ubiquitous and critical to the func-
tion of almost all biological systems and can be highly
selective and very efficient. Beyond their respective roles
in the natural systems of origin, they have found numer-
ous significant roles in commercial enterprises such as
pharmaceuticals, foods and beverages, biofuels, deter-
gents, biodegradable plastics, animal feed, and textiles to
name a few. They can be optimized for specific industrial
applications outside of their native substrate affinity, tem-
perature, pH, etc., using a variety of genetic engineering
and selection techniques. Although significant progress
has been made, there remain fundamental limits to their
performance that motivate the discovery of synthetic
enzymes that possess all of the positive attributes of
native enzymes but have superior performance in terms
of lifetime and operating environments.
The notion of synthetic enzymes has been mentioned
in the scientific literature as early as 1908 (Stangas-
singer, 1908). Since that report, researchers have been
working towards synthetic enzymes that use enzymes
as a reference template for ‘bioinspired’ artificial cata-
lysts capable of performing identical reactions in very
different chemical environments. The classic work of
Pauling (1946) hypothesized that the enzyme has weak
interactions with the substrate that stabilizes a transition
state that induces catalysis. The design of synthetic
enzymes therefore requires a deep fundamental under-
standing of the exact nature of this transition state as
well as the sequence- and structure-based origins of
enzymatic biocatalysis.
There have been several examples that highlight the
potential power of synthetic enzymes. Instead of relying
on proteins to serve as the catalytic scaffold, DNA has
been shown as being capable of performing enzyme-like
catalysis (termed DNAzymes) for the cleavage of RNA,
RNA ligation, and as therapeutic agents capable of
mRNA cleavage in vivo (Schlosser and Li, 2009). Pro-
fessor Roger Sheldon’s group at the Delft University of
Technology has demonstrated several examples of
altering the native biochemical activity of enzymes. For
example, they added a metal in the active site of
hydrolytic enzymes in order to mediate certain targeted
chemical reactions of interest such as oxidations and
through the addition of vanadium to develop a semi-
synthetic vanadate phytase peroxidase (Sheldon, 2008).
Other approaches have been used to create synthetic
enzymes from polyleucines and other polyamino acids
capable of aldol condensation between cyclohexanone
and various aromatic aldehydes, as well as the enanti-
oselective epoxidation of chalcone (Colonna et al.,
2009). Finally, tetranuclear zinc clusters have been uti-
lized as synthetic lipases in the enantioselective acyla-
tion of alcohols (Ohshima et al., 2008).
So what is there left to do in the field of synthetic
enzymes that warrants excitement today? For starters, we
are approaching the very real convergence of combinato-
rial chemistry and new fundamental understandings of
enzymatic biocatalysis enabled by the current revolutions
underway in the fields of high-throughput sequencing and
bioinformatics. This combination gives researchers the
tools required to develop new strategies of equivalent
directed evolution and genetic engineering screening
approaches in the discovery and optimization of synthetic
enzymes capable of performing specific functions on a
wide range of substrates with no loss of performance, and
do so efficiently in industrial environments that would
denature proteins. When combined properly with the
knowledge of the specific structure- and sequence-based
motifs that enable enzymes to efficiently interact with the
transition state of the substrate, researchers should now
be able to draw correlations from the cheminformatic and
bioinformatic databases available to identify and optimize
new chemomimetic synthetic enzymes. If successful,
these results could have a significant impact on a diverse
range of significant commercial pursuits that would
benefit from the availability of synthetic enzymes, includ-
ing renewable energy, artificial photosynthesis, human
health, chemical and polymer manufacturing, and carbon
sequestration.
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Visions about water and sanitation for the cities
of the future: time to rethink environmental
microbial processes
Willy Verstraete and Bart De Gusseme, Laboratory of
Microbial Ecology and Technology (LabMET), Depart-
ment of Biochemical and Microbial Technology, Ghent
University, Ghent, Belgium
Anno 2010, water microbiologists and process engineers
are with good reason technological positivists. They are
able to treat a very complex mix of chemicals and mate-
rials dissolved and suspended in water in such a way that
common sewage is converted into NEWater (Qin et al.,
2004). It is a remarkable demonstration of technical inge-
nuity. Indeed, one can now eliminate major pollutants
such as organics (BOD) nutrients (N and P) but also trace
organics (pesticides, pharmaceuticals and personal care
products) and all forms of disease-causing agents at a
reasonable price of a few euro per m3 drinking water
produced, even when starting from very polluted sources
such as domestic wastewaters. Yet, when looking world-
wide, it appears that one out of eight persons has as yet
no access to nearby drinking tap water (WHO-UNICEF,
2010). Some 1.6 million children die each year by simple
diarrhoea as a result of intake of unsafe water (compare
with AIDS: 280 000 victims per year). The best environ-
mental technology that we have for the poor is SODIS, i.e.
a PET plastic bottle that is exposed to sunlight for several
hours (Dejung et al., 2007). Indeed, only the latter tech-
nology can be applied in such regions, not imposing
excessive costs for the people. From this point of view, we
have to reconsider our positivism.
In the cities of the past, sanitation has always been a
problem. It has gradually been resolved around 1850. Yet,
the toilet with a water footprint of 40 to 70 l per capita per
day will be ‘unsustainable’ in many places in the future. The
mega cities of tomorrow have to reconsider the actual
sanitation approach, which is entirely based on flushing
excrements out of the city surroundings by use of ample
amounts of water. Currently, 2.6 billion people have no
access to decent sanitation (WHO-UNICEF, 2010).Amajor
additional difficulty is that sanitation is taboo in many
cultures, religions and let us be frank, to a large extent also
in science. How much opportunity for a high level research
grant does one have with a project focussed on sanitation?
A remarkable exception in this respect is the Bill & Melinda
Gates Foundation, providing stimuli for researchers to
improve hygiene, sanitation and access to clean water (Bill
& Melinda Gates Foundation, 2010).
Several microbial processes are out of date and/or out
of place
The urban metabolism is at present fixed on the concept
of ‘disposal from the site of production’ and ‘total dissipa-
tion’. Food wastes, which often represent up to 10–20% of
the overall energy budget of the citizen (Cuellar and
Webber, 2010), must be used to be the driver of the new
sanitation. Indeed, they can, together with the less appre-
ciated faecal wastes, be digested to valuable biogas (Ma
et al., 2009). The anaerobic digestion process offers the
possibility to recover the energy that is in the residue.
Concomitantly, the overall mix is to a large extent pasteur-
ized, particularly if the digestion is done under thermo-
philic conditions. Moreover, the thus hygienized residual
liqour can be further used or treated to recover the fertil-
izer nutrients it contains. The digestion and further treat-
ment can be done at a centralized but also at a
decentralized level (Elmitwalli et al., 2006; Zeeman et al.,
2008; Vlaeminck et al., 2009). In the former case, the
upgrading of the recovery product can be technically
assured to a high degree. In the latter case, an incentive
for the local citizens to cooperate in terms of safeguarding
the overall process can be generated. In this respect, for
such a drastically new approach focussed on recovery,
one can roughly estimate that the costs for treating the
sanitary wastes, which overall amount between 30–100
EUR per inhabitant per year, can be minimized and even
in some instances might be turned to benefits (Verstraete
et al., 2009).
Two other aspects require consideration. First, the large
amounts of water used now to flush the wastes are in many
instances not available. In view of the many taboos, it
appears that the NoMix toilet (Larsen and Gujer, 1996), in
which urine and faeces are not mixed, offers no major
obstacles to various religions and cultures (Lienert and
Larsen, 2010). Hence, by designing separate lines for
transport and treatment of these two types of excrements,
one can considerable advance the opportunities for recov-
ery of energy, nutrients and water. Indeed, the faecal
matter can with other organic wastes (e.g. kitchen organ-
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ics) be recovered in the form of a concentrated slurry, which
offers much better possibilities for affordable ‘Cradle to
Cradle’ treatment as outlined above (Verstraete et al.,
2009). Alternatively, urine is in most cultures not consid-
ered as very offensive. Clever processes to recover the
substantial amount of nitrogen and phosphorous in urine
are already existing. For developing countries, a promising
new nutrient recovery process is nitrification in sand filters
and solar evaporation (Pronk and Kone, 2009).
Second, we should face the fact that in our current way
of treating wastewater, we destroy all nitrogen by first
nitrifying it and then denitrifying it to dinitrogen gas. The
phosphorous, also the biologically harvested one, gener-
ally ends up in the landfill either in the form of bio-solids or
as ashes from the incinerated sludge. Yet, the nitrogen
represents fossil fuel (1 kg of fertilizer nitrogen requires
about 1 l of fuel equivalent). Phosphorous is mainly mined
in the USA, Morocco and China and the reserves are
rapidly decreasing. Some forecast that they are only
lasting for 50–100 years (Cordell et al., 2009). Hence, it
stems to reason that we totally redesign our current
sewage treatment because at present it is entirely con-
ceived in the context of the past century. which had as
prime message to remove and dissipate the waste, rather
than to recover to the maximum the valuable components
it represents.
Overall, environmental microbiologists have done a
good job until now. Yet, both in the perspective of the
requirements for a global sanitation and the need to gen-
erate a sustainable bio-economy, there is an urgent need
to totally rethink and redesign the various currently used
process lines in dealing with urban metabolism. The key
process to advance is anaerobic digestion. Microbial pro-
cesses to reconsider critically and most possibly to
abandon in the treatment design are nitrification, denitri-
fication, biological phosphate removal and aerobic com-
posting. To make the cities of the future sustainable, we
will have to redirect the implementation of certain micro-
bial services. If we like it or not. And it is our duty to
convince architects and urbanists that new processes and
biotechnologies are ready to be implemented for new and
much more clever sanitation.
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Stand alone biofuel production from algae
Rene H. Wijffels and Marcel Janssen, Bioprocess Engi-
neering, Wageningen University, Wageningen, The
Netherlands
Maria J. Barbosa, Food and Biobased Research,
Wageningen University and Research Center, Wagenin-
gen, The Netherlands
Will algae keep their promise?
Microalgae have been promising for the last 60 years but
so far did not prove their potential. Still many think today it
will be the future feedstock for food and fuel. We believe
algae will keep their promise and recently published a
paper envisioning that we still need 10–15 years to develop
the technology from a craft that it is today to a commercial
industrial activity (Wijffels and Barbosa, 2010).
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There are a few winning features of microalgae which
will make this happen:
(i) microalgae are very productive;
(ii) it is the shortest route from solar energy to functional
molecules;
(iii) microalgae can be grown in salt water; and
(iv) supply of nutrients like phosphate is more efficient for
aqueous biomass than for land crops (phosphate will
not be chemically immobilized like in soil).
The cost of production of microalgae can become a lot
lower than today (Norsker et al., 2011) and will become
cost-effective if the algal biomass is ‘biorefined’ (Wijffels
et al., 2010) and there is sufficient area available for pro-
duction of microalgae to provide the entire transport Euro-
pean fuel market with algal oil without putting any
pressure on food supply (Wijffels and Barbosa, 2010).
In the USA there are many projects in the area of
synthetic biology of microalgae. In comparison, much
smaller budgets are available for that in Europe. On the
other hand it is surprising that there is a relative lack of
innovative technology development in the USA. Algal
strains that were specially designed for certain purposes
could never perform optimally in open systems where
many process parameters cannot be controlled. In the
fields of photobioreactor design, continuous operation of
systems and biorefinery, which are all essential technolo-
gies for full-scale cultivation of algae, the position in
Europe is stronger than in the USA. We need to integrate
research on synthetic biology with innovative process
principles to make progress in the field.
Apart from these optimization issues, which provide a
challenging research area on which we should focus
anyhow in the coming years, we would like to address
three crystal balls that would turn microalgae into a very
competitive crop: these are water, phosphate and CO2.
Production of microalgal oil can be done in stand alone
systems if these crystal balls become reality.
Water
The fact that algae can grow on salt water makes them
superior to most land crops. Because of that, algae can be
grown in deserts in the condition that evaporation of water
is prevented and in large ocean water bodies. For produc-
tion of biofuels from land crops thousands of litres of fresh
water per litre of biofuel are required while potentially in
the case of microalgae, a few litres would be sufficient
(Wijffels and Barbosa, 2010). That is if the technology is
developed in which cooling is not done via evaporation of
water but via heat exchange in the large water bodies as
mentioned. Production in the open ocean would be attrac-
tive in that respect; however, we need to realize that
offshore production is complex in respect to controllability
and logistics and may result in an increase in production
costs. If production of microalgal oils will take place in
remote areas, logistics for the supply of nutrients will
represent a major challenge to address. On the other
hand, it provides an opportunity. An example of a nice
project for nutrient recycling in offshore systems is the
omega project of NASA (http://www.nasa.gov/centers/
ames/research/OMEGA/index.html).
Phosphate
One of the most critical nutrients on our planet is phos-
phate. It is estimated that our phosphate reserves will be
gone within a period of 100 years (Vaccari, 2009). Phos-
phates are mined, used as fertilizer for crops and taken up
inefficiently because phosphate binds to the soil. As such,
via production of aqueous biomass, the efficiency of phos-
phate utilization would increase as the phosphate sup-
plied will not bind to soil. Nevertheless, if we produce
biofuels because we run out of fossil fuels we would not
solve our problem if we will run out of phosphate at similar
rates instead.
Transport fuels do not contain phosphate. Ideally they
consist of hydrocarbons without any phosphate. Objective
should therefore be to produce algae lipids without adding
phosphate. A couple of years ago we developed the
concept of milking of microalgae (Hejazi and Wijffels,
2004) in which the microalga Dunaliella salina was used
as a photocatalyst for the continuous production and in
situ extraction of carotenoids in a two-step process. First
the microalga was grown up to a certain biomass concen-
tration after which carotenogenesis was induced and
carotenoids were continuously extracted with an organic
solvent. In this way carotenoids were directly produced
from only CO2, water and light energy. Our first hypothesis
was that this process was conducted without damaging
the cells but recently we demonstrated that direct contact
between the solvent and the algae resulted in cell death of
D. salina (Kleinegris et al., 2010). The concept is still very
much alive, and could be potentially used if the product is
excreted. As an example, cyanobacteria were developed
that are able to produce and excrete higher fatty acids.
New pathways were engineered for this and transporter
genes were introduced (Liu et al., 2010). This opens the
possibility to use cyanobacteria as a catalyst and to
produce higher alcohols under nutrient starvation condi-
tions in continuous culture. If such concept is further
developed and applied to microalgae we will really be able
to produce biofuels from algae in a sustainable way.
CO2
An essential substrate for algae production or lipid
production in microalgae is CO2. Effective production
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can only take place if the concentration of CO2 is higher
than atmospheric levels despite the greenhouse effect.
Although society overproduces CO2, it is not produced at
the locations where we would like to grow algae (in
deserts and on the ocean). Active supply of CO2 to pro-
duction systems at these locations would be logistically
complex and very expensive. Ideally algae should grow
effectively at atmospheric CO2 pressures. A number of
crops solved this problem via the enzyme carbonic anhy-
drase (Furbank et al., 1989). Carbonic anhydrase pro-
vides a CO2 concentrating mechanism in the cell. Many
microalgae also contain carbonic anhydrase and so also
for microalgae this principle might be applicable (Aizawa
and Miyachi, 1986). Largest bottleneck seems to be to
keep the CO2 concentration in the water phase in equilib-
rium with the atmospheric CO2 concentration.
Stand alone oil production from algae
Production of algae in photobioreactors is going to be
cheaper and closed systems are the only way to be able
to produce microalgae without excessive needs of fresh
water. If the microalgae have the ability of catalytic lipid
production and excretion, nutrient inputs can be reduced
substantially. Ideally algae should grow on atmospheric
CO2 such that no active supply of CO2 needs to take
place.
If (and all concepts are there) we are able to produce
algae with limited amount of fresh water, without phos-
phate on atmospheric CO2 we will be able to develop a
stand alone system from which we only need to collect the
oil. In that case all the requirements are present to
develop a scalable system.
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Tapping into ancient medicine for today’s problem
with functional metagenomics
Liping Zhao, Shanghai Center for Systems Biomedicine,
School of Life Sciences and Biotechnology, Shanghai Jiao
Tong University, Shanghai 200240, China
Jeremy K. Nicholson, Department of Surgery and Cancer,
SORA Division, Faculty of Medicine, Imperial College
London, South Kensington SW7 2AZ, UK
Traditional Chinese medicine (TCM) incorporates an
ancient set of empirical observations and multiple thera-
pies that are at least in part congruent with recent con-
cepts in polypharmacy (multiple therapeutic targeting)
where herbal decoctions contain many biologically active
natural products many of which may act synergistically
(Wang et al., 2008). This methodology seems to be effec-
tive for managing chronic diseases, which have become a
devastating epidemic worldwide. TCM is also the ultimate
exemplification of personalized healthcare using non-
invasive whole body diagnostic methods to stratify
patients into subclasses who then receive a specifically
tailored therapy often consisting of herbal decoctions,
dietary and lifestyle management. Framed in this way
TCM seems remarkably modern, yet we still have a poor
understanding of the modes of action and relative efficacy
of most TCMs compared with western drugs. Also, the
laudable ‘personalized and holistic nature’ of TCM also
makes it more difficult to apply randomized, double-
blinded and placebo-controlled trials used in mainstream
medicine. This has seriously hampered the integration of
TCM into modern medical scheme, but with the advent of
top–down systems biology tools with gut microbiota as the
primary target, there may be new ways to understand and
assess these therapies.
Recent evidence suggests that diet and herbal medi-
cines interact strongly with the gut microbiome, which in
turn also influences human health (Jia et al., 2008) and we
have recently shown that population phenotype variation
links to disease risk factors and that a significant part of the
human metabolic phenotype may be influenced by micro-
bial activity variation (Holmes et al., 2008). As most
Chinese and other herbal medicines are orally adminis-
tered, the host-microbial-metabolic axis (Nicholson, 2006)
may be an important and as yet little studied part of TCM
action and it is even possible that TCMs may work largely
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by drugging or modulating this axis (Jia et al., 2008).
Hence application of the new palette of metabolic pheno-
typing and metagenomic screening technologies to look at
linked temporal variation of metabolites and microbes (Li
et al., 2008) post-TCM treatment may provide new molecu-
lar evidence to verify or disprove the efficacy of such
therapies. In this new functional metagenomic screening
paradigm, urinary metabolites and gut bacteria would
provide two non-invasive parameter windows indicative of
the global health status of individual patients, thus can offer
systems and quantitative assessment of health responses
to TCM or any other types of alternative therapeutics.
To understand this new systems biology approach, it
must be emphasized that human beings are superorgan-
isms (Lederberg, 2000) with multiple interacting genomes
including the relatively fixed and genetically inherited
human karyome (c. 21 000 genes) and the environmen-
tally acquired and plastic human gut microbiome (> 1
million genes). Humans and their symbionts need to be
harmoniously integrated to maintain our metabolism and
hence health and the functional footprints of gut metage-
nome can be observed in urinary polar metabolite profiles
(Li et al., 2008).
To evaluate a TCM therapy with temporal functional
metagenomics, a group of healthy people will first be
selected to establish a population specific reference
dataset (German et al., 2005), which will define the bound-
ary of metabolic and metagenomic diversity spaces of
healthy local people. Patients who receive any particular
form of TCM therapy will be monitored by collecting their
urine and faecal samples before, during and after the
intervention together with all relevant clinical data. The
metabolic or metagenomic trajectory of each patient will be
calculated by comparing with all the other patients and the
reference population with multivariate statistics to monitor
if distance between a particular patient and the reference
health population is decreased, increased or maintained in
response to interventions. The reference population will
define a target space towards which all the patients should
move to if the intervention they receive improve their health
conditions. If the intervention has some adverse effect we
can expect that the patients will move in a different meta-
bolic direction within the hyperspace and away from the
reference population. In principle, this scheme can be used
to test if a therapy has any effects in single individuals. This
makes clinical trials for personalized therapy possible
using each as their own control. This approach can also be
used to evaluate efficacy or toxicity of one particular
therapy to many individuals to show that if a particular
measure for preventing a disease is actually working in the
targeted populations. If a particular therapy showed the
capacity to move the treated patients towards the meta-
bolic space of the reference health population, the respon-
sible biomarker variables can be identified via appropriate
statistics. The identified urinary metabolites or gut bacterial
species can be used as a starting point to formulate
hypothesis regarding why a therapy can change these
biological parameters.
This new temporal functional metagenomic approach
may provide a powerful new tool for evaluating TCM
therapies in the context of patient monitoring and stratifi-
cation based on a holistic view of the human body includ-
ing the metagenome. The integration of TCM with modern
non-invasive ‘omics’ platforms not only offers a new
lease-of-life to TCM, but could also transform this ancient
empirical practice into evidence-based science and a new
source of therapies for meeting 21st century global health
challenges.
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Weaving a synthetic harness for the biosynthesis of
natural products
Sergey B. Zotchev, Department of Biotechnology, Norwe-
gian University of Science and Technology, Trondheim,
Norway
Introduction
Natural products provide a wide array of molecules with
diverse biological activities, some of which have been
Crystal ball 135
© 2011 The Authors
Journal compilation © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd, Microbial Biotechnology, 4, 109–137
successfully developed into drugs for human medicine
(e.g. antibiotic erythromycin, immunosuppressant rapa-
mycin, anticancer drug doxorubicin etc). However, a
number of publications in the last 5 years suggest that
drug development pipelines, especially those based on
natural products, are drying out in many pharmaceutical
companies. Although there are several reasons for that,
one of the most important one is related to frustration
caused by continuous rediscovery of natural bioactive
compounds in extensive screening programs. This is
probably not surprising, considering the fact that many
such molecules are produced by living organisms as sec-
ondary metabolites only in response to certain stimuli,
which are difficult or impossible to reproduce in the lab.
Consequently, an array of molecules produced in a limited
set of conditions we are able to create in the lab will be
overpopulated by the same secondary metabolites. At
the same time, recent sequencing of genomes of several
antibiotic-producing bacteria revealed that their genetic
potential for production of secondary metabolites is far
greater that could have been assumed based on the
phenotypic data. Although now we can very often link
certain genes with the biosynthesis of specific molecules
(Walsh and Fischbach, 2010) important questions about
the practical use of such information remain: How can we
exploit such potential for discovery of new bioactive mol-
ecules? Can we make completely new ‘designer’ mol-
ecules with predictable pharmaceutical properties based
on integration of bio- and chemoinformatics and genetic
engineering? Can synthetic biology help here?
‘Early birds’
Although there are yet not many examples that can
support a ‘yes’ answer to these questions, certain trends
began to emerge recently. The work by Menzella et al. in
2005 has demonstrated that synthetic DNA fragments
encoding parts of modular polyketide synthases can be
mixed-and-matched to produce functional biosynthetic
enzymes (Menzella et al., 2005). Although not followed
up, this work exemplifies the significance of rapidly
evolving technology for DNA synthesis for engineering of
natural product biosynthesis.
Perhaps the most important ‘early bird’ paper on the
application of synthetic biology for the sustainable produc-
tion of a drug precursor has been the one published by
J.D. Keasling’s group in 2006 (Ro et al., 2006). Clearly,
this publication, describing functional ‘synthetic’ biochemi-
cal pathway for production of an antimalarial drug precur-
sor, has received considerable attention from many
researchers studying biosynthesis of natural products.
The mix-and-match approach that supporters of ‘combi-
natorial biosynthesis’ were hoping to utilize for discovery
of new drug leads received a new dimention.
So why have we not yet seen many successful
examples of drug discovery-oriented projects based on
synthetic biology approaches? I believe the main reason
for that is reluctance of many scientists applying engi-
neering principles to biology (synthetic biologists) to
enter precarious routes of biosynthetic engineering. This
is understandable, considering the biochemical complex-
ity of secondary metabolite biosynthesis pathways,
number of genes and proteins involved, several levels of
regulation usually imposed by the hosts on such path-
ways etc. While synthetic biologists aim at creating stan-
dard connectable ‘parts’ and ‘devices’, each secondary
metabolite biosynthesis pathway contains a unique com-
ponent, standardization of which might represent a for-
midable task, or is not at all needed as a result of its
uselessness in other applications. How can we engage
synthetic biology into the natural product-based drug dis-
covery programs?
Current status
Several research groups have recently reported suc-
cessful heterologous expression of gene clusters for bio-
synthesis of natural products, although the level of
molecule production remains low (reviewed in Baltz,
2010). Others have used a strategy of activating silent
gene clusters to achieve production of new molecules
(Gottelt et al., 2010). These are certainly very useful
approaches expanding the chemical diversity in natural
products-based drug discovery programs. However, they
are still based on the traditional mode of thinking about
the complex biosynthetic pathways, and are not robust
enough for projects focused on drug discovery. New,
out-of-the-box ideas on how complex biosynthetic path-
ways are functioning and how to regulate metabolic
fluxes in such pathways are currently emerging. For
example, the recent use of synthetic protein scaffolds in
order to ‘encage’ anabolic enzymes and force their effi-
cient interaction has led to a very significant increase in
the efficiency of a biosynthetic pathway (Dueber et al.,
2009). Also, a recent publication on a synthetic biology-
based fine-tuning of ribosomal binding sites (RBS)
aimed at optimization of protein expression (Salis
et al., 2009) sparks new ideas. Indeed, traditionally,
researchers were focusing on transcriptional regulation
of biosynthetic pathways and regulation on the level of
translation has been, for the most part, ignored. It seems
likely that at least in some cases of failed heterologous
expression of biosynthetic pathways suboptimal interac-
tion of the host’s ribosome with the heterologous RBS
might be the reason for failure. If so, synthetic biology
can be used to optimize RBSs within the biosynthetic
gene clusters in order to adapt them to particular
hosts.
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Future trends
What kind of future developments can we expect in the
field of natural product biosynthesis applied to drug dis-
covery in the next 10–15 years?
Certainly, as the applications of synthetic biology prin-
ciples gain momentum, and prices for de novo DNA syn-
thesis continue to fall, more ‘synthetic’ parts will be used
for re-engineering (or, using synthetic biology wording,
‘re-factoring’) of biosynthetic pathways. Not only parts,
but complete biosynthetic pathways will be synthesized
de novo based on computer-generated design that will
take into account both the genes specifying and control-
ling these pathways and the genetic make-ups of the
hosts where these pathways will operate. For the latter,
systems biology advances in understanding the meta-
bolic networks and modelling of cell’s metabolism will
play a crucial role. First attempts to aid this task, and to
minimize complexity of the model through minimization of
host’s genome have been published (e.g. Komatsu et al.,
2010).
I also predict that considerable progress will be made
towards application of the ‘combinatorial biosynthesis’
principle to drug discovery using synthetic biology.
Indeed, the latter opens completely new opportunities for
gene combination in totally synthetic, artificial biosynthetic
pathways for generation of small molecules with drug-like
properties. This, however, will not be possible without
significant breakthroughs in the filed of computational
biology and chemistry. Ideally, as a starting point, a new
pipeline for drug development would take a specific thera-
peutic target (e.g. an enzyme) that has to be modulated
by a small molecule. Computer modelling shall generate a
suggestion for a chemical structure of a small molecule
that can bind the enzyme and modulate its activity. Next,
a specially designed computer program based on the
wealth of information available on the biosynthesis of
natural products shall suggest how this molecule can be
biosynthesized. Computer-based assembly of genes for
biosynthetic enzymes and in silico fine-tuning of their
expression based on the information on the host would be
followed by synthesis of artificial gene cluster and its
functional expression.
Wishful thinking? Yes, may be so, but the history has
proven many times over that technological progress can
sometimes outpace our wildest imagination. As my col-
league Svein Valla has written 2 years ago in the Crystal
Ball feature, ‘the future is artificial’, but I would add –
naturally so.
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